ArticlePDF AvailableLiterature Review

Abstract and Figures

Tau protein is abundant in the central nervous system and involved in microtubule assembly and stabilization. It is predominantly associated with axonal microtubules and present at lower level in dendrites where it is engaged in signaling functions. Post-translational modifications of tau and its interaction with several proteins play an important regulatory role in the physiology of tau. As a consequence of abnormal modifications and expression, tau is redistributed from neuronal processes to the soma and forms toxic oligomers or aggregated deposits. The accumulation of tau protein is increasingly recognized as the neuropathological hallmark of a number of dementia disorders known as tauopathies. Dysfunction of tau protein may contribute to collapse of cytoskeleton, thereby causing improper anterograde and retrograde movement of motor proteins and their cargos on microtubules. These disturbances in intraneuronal signaling may compromise synaptic transmission as well as trophic support mechanisms in neurons.
Content may be subject to copyright.
Int. J. Mol. Sci. 2014, 15, 4671-4713; doi:10.3390/ijms15034671
International Journal of
Molecular Sciences
ISSN 1422-0067
Tau Protein Modifications and Interactions:
Their Role in Function and Dysfunction
Anna Mietelska-Porowska, Urszula Wasik, Marcelina Goras, Anna Filipek and
Grazyna Niewiadomska *
Nencki Institute of Experimental Biology, Polish Academy of Science, 3 Pasteur Street,
Warsaw 02-093, Poland; E-Mails: (A.M.-P.); (U.W.); (M.G.); (A.F.)
* Author to whom correspondence should be addressed; E-Mail:;
Tel.: +48-22-589-2409, Fax: +48-22-822-5342.
Received: 29 November 2013; in revised form: 11 February 2014 / Accepted: 4 March 2014 /
Published: 18 March 2014
Abstract: Tau protein is abundant in the central nervous system and involved in
microtubule assembly and stabilization. It is predominantly associated with axonal
microtubules and present at lower level in dendrites where it is engaged in signaling
functions. Post-translational modifications of tau and its interaction with several proteins
play an important regulatory role in the physiology of tau. As a consequence of abnormal
modifications and expression, tau is redistributed from neuronal processes to the soma
and forms toxic oligomers or aggregated deposits. The accumulation of tau protein is
increasingly recognized as the neuropathological hallmark of a number of dementia
disorders known as tauopathies. Dysfunction of tau protein may contribute to collapse of
cytoskeleton, thereby causing improper anterograde and retrograde movement of motor
proteins and their cargos on microtubules. These disturbances in intraneuronal signaling
may compromise synaptic transmission as well as trophic support mechanisms in neurons.
Keywords: tau protein; cytoskeleton; microtubule; tau kinases and phosphatases;
tau interacting proteins; neurodegenerative disorders; neurotrophic support
Int. J. Mol. Sci. 2014, 15 4672
1. Introduction
Tau protein belongs to the family of natively unfolded microtubule-associated proteins that binds to
microtubules, is involved in their assembly and stabilization [1] and in regulation of the motor-driven
axonal transport. Earlier work showed that tau is concentrated predominantly in neuronal
axons [2,3]. However, recent data suggest that tau also might play a physiological role in
dendrites [4–6]. Six tau isoforms, produced by alternative mRNA splicing of the MAPT gene located
on chromosome 17q21.31, are expressed in the adult human brain [7]. Each isoform contains either 3
(3R) or 4 (4R) repeat domains responsible for the interaction with microtubules. In the cerebral cortex
of healthy adults the amounts of 3R and 4R tau are equal [8]. It has been also found that the expression
of tau is roughly two-times higher in grey matter of the neocortex when compared to white matter or to
the cerebellum [9].
Tau function depends on its phosphorylation state [10,11]. The incorporation of phosphate groups
into tau depends on its conformation and on the balance between the activities of tau kinases and
phosphatases. Changes in tau conformation could result in increased phosphorylation and in decreased
binding to microtubules which is important in tau-mediated neurodegeneration [12]. Excessively
phosphorylated tau accumulates in the somatodendritic compartment of neurons, aggregates and
eventually forms neurofibrillary tangles (NFTs) [13]. There is an evidence that soluble overly
phosphorylated tau contributes to neuronal dysfunction before its deposition [14]. It has been shown
that highly phosphorylated tau interferes with neuronal functions, such as mitochondrial respiration
and axonal transport [15,16]. Biochemical and immunostaining data indicate that overphosphorylated,
aggregated tau makes up the intracellular filamentous inclusions present in many human
neurodegenerative diseases collectively named tauopathies.
Tau excessive phosphorylation and aggregation could be driven by its interaction with several other
proteins like β-amyloid, Fyn kinase, Pin1, heat shock cognate Hsc70 and heat shock protein Hsp90,
immunophilins FKBP51 and FKBP52, α-synuklein or actin interacting protein PACSIN1. As the
consequence of these interactions tau accumulates in dendritic spines, where it suppresses synaptic
responses [17,18]. In neurons excessively phosphorylated tau is involved in: microtubule
destabilization, impaired axonal transport of substances [19], post-synaptic dysfunction, compromised
cell signaling and, as consequence, cognitive impairments ensue [20].
2. Tau Protein
Tau protein is widely expressed in the central and peripheral nervous system, but is also present in
kidney, lung and testis [21]. Although tau is most abundant in axons [22–25], it is also found in
somatodendritic compartments [26] and in oligodendrocytes [27].
Biophysical studies revealed that tau has hydrophilic properties and the protein exists normally as a
natively unfolded or intrinsically disordered protein [28,29]. The polypeptide chain of tau is highly
flexible and mobile and has only a low content of secondary structures (α-helix, β-strand, poly-proline
II helix). Primary sequence analysis demonstrates that the tau molecule contains three major domains,
defined on the basis of their microtubule interactions and/or their amino acid character: an acidic
N-terminal part; a proline-rich region and a basic C-terminal domain. Thus, tau protein is a dipole with
Int. J. Mol. Sci. 2014, 15 4673
two domains having the opposite charge [30]. This asymmetry of charges is crucial for interactions
between tau and microtubules and other partners as well as for internal folding and aggregation [31].
The C-terminal domain binds to microtubules and promotes their assembly and is termed the
“assembly domain” [32]. Binding to microtubules occurs through repeated domains (R1R4) encoded
by exons 912. Each repeat consists of highly conserved stretches of 18 residues. The repeats are
separated from each other by 13- or 14-residue spacer regions [33]. Many studies support a role for the
assembly domain in the modulation of the phosphorylation state of tau protein. A direct and
competitive binding has been demonstrated between the region of tau containing residues 244–236
(numbering of amino acids is that of the longest human tau) and the microtubule or protein
phosphatase 2A (PP2A). As a consequence, microtubules could inhibit PP2A activity by competing for
binding to tau [34].
The middle region of tau residues 150240 contains numerous prolines, which are targets of many
proline-directed kinases and binding sites for proteins with SH3 domains. This part of the tau molecule
is termed as a “proline-rich domain” [31].
The acidic N-terminal part of tau does not bind to microtubules but projects away from the
microtubule surface and is termed “projection domain” [35]. This domain of tau may interact with
other cytoskeletal elements, mitochondria or neuronal plasma membrane [36–38] and it may determine
spacing between microtubules in the axon [39]. In peripheral neurons tau contains an additional
N-terminal sequence encoded by exon 4A which generates a specific peripheral neuron isoform called
“big tau” [40].
3. Role of Tau Protein in Neurons
The tau is a multifunctional protein [41–43] (Figure 1). It has numerous binding partners, including
signaling molecules, cytoskeletal elements and lipids. The most important function of tau is its role in
tubulin polymerization. On tubulin, the tau interacting site is located at the C-terminal end, which is
highly acidic. Binding of tau to tubulin is regulated by post-translational modifications, especially by
phosphorylation. Phosphorylation may neutralize the positive charge [44], alter the conformation and
detach tau from microtubules [45]. In pathological conditions, tau self-polymerization and aggregation
might also affect the tau-tubulin binding [46]. Tau may interact with microtubules directly and
indirectly. Direct interactions include the binding, stabilization and promotion of microtubule
assembly [47]. The ability of tau to bind microtubules depends on the microtubule-binding domain and
on adjacent regions [48]. Indirect interaction of tau with microtubules affects other proteins that may
or may not interact with microtubules by themselves. These interactions may require the projection
domain of tau [31,49].
Int. J. Mol. Sci. 2014, 15 4674
Figure 1. Tau is a multi-functional protein. As a microtubule-associated protein tau
contributes to microtubule dynamics and participates in neurite outgrowth, axonal transport
and trophic signaling enhancement. Moreover, tau participates in cell signal transduction
through the modulation of the activity of Src and Fyn kinases and PSD95 protein.
In the nucleolar organizing region of cell, tau can also be involved in DNA repair and heat
shock responses (left panel). Tau dysfunction leads to microtubule disintegration, tau
filaments formation and intraneuronal signaling disorder and, as a consequence, to cell
death (right panel).
Int. J. Mol. Sci. 2014, 15 4675
The adult forms of tau promote assembly of microtubules more actively than the foetal form [29].
The recent studies concerning the physical interaction between tau and microtubules indicated that,
while all repeats contacted the microtubules, there were specific sequences that were strongly involved
in the interaction [50]. These sequences included
. In addition, residues in the flanking regions as far upstream as S214 and as far
downstream as L375 were also involved, with
having especially
strong interactions [50,51]. Both sequences
are coded by exon 10
and this may explain why 4R tau isoforms interact with microtubules more strongly than 3R tau
isoforms [52]. The repeat sequences are thought to directly bind microtubules through their positive
net charge, which interacts with negatively charged residues of tubulin monomers [44]. Tau can bind
outside and inside of microtubules, with its N- and C-terminal domains [38,53].
Binding of tau to microtubules can take part in axonal transport and can interfere with the binding
of motor proteins [12]. A gradient of tau along the axon with the highest level around the synapse [54]
might facilitate the detachment of motor proteins from their cargo near the presynaptic terminal and
in consequence might increase axonal transport efficiency [12]. As to the interactions with other
cytoskeletal components, tau binds to spectrin and actin filaments [55,56]. This might allow
tau-stabilized microtubules to interconnect with neurofilaments that restrict the flexibility of the
microtubule lattices [57].
Tau can also act as postsynaptic scaffolding protein. As a scaffold protein, tau modulates the activity of
Src tyrosine kinases, c-Src and Fyn, and facilitates c-Src-mediated actin rearrangements [58]. In the case
of Fyn, it has been suggested that tau normally tethers Fyn to PSD-95/NMDA receptor signaling
complex [4]. In the absence of tau, Fyn can no longer traffic into postsynaptic sites in dendrites.
Although normally very little tau is present in dendrites, probably it is enough to ensure proper
localization of postsynaptic components [4]. Tau can also act as a scaffold protein in oligodendrocytes,
where it might connect Fyn and microtubules in order to enable processes extension [27].
Another function of tau is involvement in growth factor signaling [59,60]. Under NGF stimulation, tau
is distributed at ends of cellular extensions, where it associated with actin in a microtubule-independent
manner [55]. Tau facilitates signaling through receptors for NGF and EGF, what may increase the
activity of the mitogen-activated protein kinase (MAPK). Some data suggest that phosphorylation
of tau on threonine 231 is necessary for the growth factor-induced activation of the Ras-MAPK
pathway [61]. It remains unverified whether tau interacts directly with growth factor receptors, but it
may facilitate signaling by binding to adaptor proteins e.g., Grb2 [62].
4. Post-Translational Modifications of Tau
Tau is highly regulated and is subject to a complex array of post-translational modifications.
It is modified by serine, threonine and tyrosine phosphorylation [63], isomerization [64],
glycation [65], nitration [66], O-GlcNAcylation [67], acetylation [68], oxidation [69], polyamination [70],
sumoylation [71], ubiquitination [72] and proteolytic cleavage (truncation) [73]. Abnormal
post-translational modifications are proposed to be the main cause of the mechanism by which tau protein
becomes a non-functional entity. Much of the evidence, to be discussed below, suggests that abnormal
phosphorylation is a key event that triggers the pathological aggregation of tau in tauopathies.
Int. J. Mol. Sci. 2014, 15 4676
4.1. Phosphorylation and Dephosphorylation of Tau Protein
Protein phosphorylation is the addition of a phosphate group by esterification at three types of
amino acids: serine, threonine and tyrosine. Phosphorylation is the most common tau post-translational
modification described. So far, 85 phosphorylation sites have been identified in the tau molecule.
The phosphorylation status of the tau is a consequence of the equilibrium between the amount and
activity of protein kinases and phosphatases. In neurodegenerative diseases tau undergoes abnormal
excessive phosphorylation.
4.1.1. Tau Kinases
Kinases which are involved in tau phosphorylation can be divided into three classes:
proline-directed protein kinases (PDPK), non-PDPK protein kinases and tyrosine protein kinases (TPK). GSK-3
Glycogen synthase kinase-3 (GSK-3), belongs to the PDPK class, and is a serine/threonine-specific
kinase whose activity is regulated by phosphorylation. GSK-3 is inactivated through phosphorylation
of serine 21 (GSK-3α isoform) or serine 9 and 389 (GSK-3β isoform). The activation of GSK-3
depends on the phosphorylation at tyrosine 279 (GSK-3α) or tyrosine 216 (GSK-3β) [74–76].
GSK-3 was identified as a tau protein kinase in the 1990s [77]. So far 42 GSK-3 phosphorylable sites
were identified in tau. Among them 29 were phosphorylated in Alzheimer disease (AD) brains [11,78,79].
The level of GSK-3 in tauopathy seems to correlate with the progress of neurodegeneration.
The postmortem analysis of brains from AD patients and age-matched control samples indicates that
the level of GSK-3 is increased in neurodegeneration [80] and the activity of GSK-3 correlates with
the increasing amount of NFTs [81]. Moreover, GSK-3β co-localizes with NFTs [82]. Additionally,
studies performed on cultured neurons have shown that the GSK-3 inhibitor, lithium, protects cells
against neurodegeneration [83,84]. Abnormally phosphorylated tau protein is also the main component
of neurofibrillary tangles found in Parkinson’s disease (PD) [85]. Increased tau phosphorylation at
Ser396 by GSK-3β has been discovered in synapse-enriched fractions taken from PD brains [86].
Moreover, tau pathology has been identified in the brains of PD patients with leucine-rich repeat
kinase 2 (LRRK2) mutations [87].
DJ-1 is a small protein, the product of a highly conserved gene that has been identified as one of the
most frequently mutated genes in familial Parkinson’s disease (PD). Recently, it has been postulated
that familial PD-associated DJ-1L166P and DJ-1D149A mutations increase tau phosphorylation by
increasing the activity of GSK-3β [88]. The link between tau phosphorylation and GSK-3 has been
shown in studies performed on transgenic mice overexpressing mutant human tau (P301L, 4RON).
This mutation is related to the tauopathy named frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17). The treatment with lithium of the aforementioned transgenic mice led to a
decrease in the level of tau phosphorylation and the level of aggregated, insoluble tau. A similar result
was obtained when another GSK-3 inhibitor, AR-A014418, was used [89]. Moreover, recently the
implication of GSK-3 in tau pathology has been confirmed using pR5 mice that express the P301L tau
mutation found in familial forms of frontotemporal dementia [90].
Int. J. Mol. Sci. 2014, 15 4677 Cdk5
Cyclin-dependent kinase 5 (cdk5), originally purified as tau kinase II, is a serine/threonine
kinase [91] which belongs to the PDPK class. Similarly, as with the case of GSK-3, cdk5 activity is
regulated by phosphorylation. Three residues seem to be implicated in this process. Phosphorylation at
tyrosine 15 activates cdk5, in contrast to phosphorylation at threonine 14 and at serine 159 that inhibits
cdk5 activity [92]. Additionally, the activation of cdk5 requires the binding of an activatory subunit,
either p35 or p25 which is generated by calpain-dependent proteolytic cleavage of p35 [92]. The cdk5
activator, p25, has a long half-life and is involved in aberrant cdk5 activity toward tau [93,94]. It has
been shown that p25 accumulates in the tauopathic brains derived from AD patients. The p25/cdk5
holoenzyme phosphorylates tau and reduces its ability to bind to microtubules. Studies performed on
primary neurons have shown that p25/cdk5 alters cells morphology, causes cytoskeletal disruption and
apoptotic cell death [95]. Silencing of cdk5 reduces the phosphorylation of tau in primary neuronal
cultures and in the brain of wild type C57BL/6 mice. In a triple transgenic mouse model of AD
disease, the knock-down of cdk5 strongly decreases the number of neurofibrillary tangles in the
hippocampus [96]. Cdk5 also seems to be involved in the regulation of tau phosphorylation by GSK-3.
Tau, cdk5, and GSK-3 are components of a 450-kDa complex in which cdk5 phosphorylates tau and
primes it for phosphorylation by GSK-3 [97]. Recently, it has been shown that the effect of cdk5 on
tau phosphorylation depends on the Pin 1 protein [98–100]. JNK
C-Jun amino-terminal kinase (JNK) belongs to the PDPK group of kinases and simultaneously to
the family of serine and threonine mitogen-activated protein kinases (MAPKs). JNK phosphorylates
tau at 12 sites, which were identified only in neurodegeneration and not in control conditions.
Immunohistochemical analysis of JNK expression in AD, Pick’s disease (PiD), progressive
supranuclear palsy (PSP) and corticobasal degeneration (CBD) unveiled its co-localization with tau
aggregates [101]. Moreover the increased level of JNK has been observed in AD brains and its
activated form (p-JNK) co-localizes with p-tau in neurons of AD patients [102,103]. CK1
Casein kinase 1 (CK1) is a family of protein kinases, non-PDPK, which in humans consists of six
isoforms derived from distinct genes with further diversity generated by alternative splicing [104].
CK1 can phosphorylate tau at Ser202/Thr205 and Ser396/Ser404 in vitro and in cell culture,
modulating its binding affinity for microtubules [105–107]. The distribution of CK1 delta (CK1δ) was
studied by immunohistochemistry. CK1δ co-localizes with NFTs in AD, Down syndrome (DS), PSP,
parkinsonism dementia complex of Guam (PDC) and with Pick bodies in PiD [108]. Moreover,
the mRNA of CK1δ is upregulated in brain derived from AD patients. There was a 24.4-fold increase
in CK1δ mRNA in hippocampus, 8.04-fold in the amygdala, 7.45 in the entorhinal cortex
and 7.30-fold in the mediotemporal gyrus of AD when compared to control brains [109].
Int. J. Mol. Sci. 2014, 15 4678 Dyrk1A
Increased non-PDPK, Dyrk1A (Dual specificity tyrosine-phosphorylation-regulated kinase 1A)
kinase immunoreactivity has been found in the cytoplasm and nuclei of scattered neurons of the
neocortex, entorhinal cortex, and hippocampus in AD, DS, and PiD [110]. Dyrk1A protein
phosphorylates the microtubule-associated protein tau at several sites, including Thr181, Ser199,
Ser202, Thr205, Thr212, Thr217, Thr231, Ser396, Ser400, Ser404, and Ser422. Phosphorylation by
Dyrk1A primes further phosphorylation of tau by GSK-3 at Thr181, Ser199, Ser202, Thr205, and
Ser208 but not by cdk5 and PKA [111–113]. Tau phosphorylation at Thr212, Ser202 and Ser404 is the
hallmark of AD and is significantly increased in Dyrk1A transgenic mice overexpressing human
Dyrk1A [110]. Moreover, a study performed using a transgenic mouse model of DS, the Ts65Dn mice,
confirmed the abnormal phosphorylation of tau upon increased Dyrk1A activity. Dyrk1A induced
tau phosphorylation inhibited tau activity to stimulate microtubule assembly and promoted its
self-assembly into filaments [109,110]. AMPK
Adenosine-monophosphate activated protein kinase (AMPK), non-PDPK, is a heterotrimeric
serine/threonine kinase. The phosphorylation of tau by AMPK takes place at several residues and
effects tau binding to microtubules [114,115]. In vitro assays showed that AMPK can directly
phosphorylate tau at Thr231 and Ser396/404. Activated/phosphorylated AMPK (p-AMPK) was
abnormally accumulated in cerebral neurons in tauopathies such as AD, tangle-predominant dementia,
PDC, PiD, and FTDP-17. Granular p-AMPK immunoreactivity was observed in apparently unaffected
neurons devoid of tau inclusion, suggesting that AMPK activation preceded tau accumulation.
Phospho-AMPK was not found in purified PHFs, indicating that p-AMPK did not co-aggregate with
tau in tangles [114]. MARKs
The microtubule-affinity regulating kinases (MARKs) belong to the AMPK branch of the CAMK
(calcium/calmodulin-dependent protein kinase) group of kinases [116]. MARKs belong to the
non-PDPK group of kinases. The MARK protein family consists of four highly conserved members
(MARK14). MARK kinases co-localize with NFTs, and the expression level of MARK proteins have
been shown to be elevated in AD brains [117]. MARKs phosphorylate tau protein at the KXGS motif
of its repeat domains. This phosphorylation leads to the detachment of tau protein from microtubules
and in consequence, to destabilization of the cytoskeleton and the tau aggregation [118,119]. Tau
phosphorylation by MARKs occurs at Ser262, 293, 324 and 356 [120,121]. Recently, it has been
postulated that MARK4 is the crucial isoform of the MARK family which is implicated in the
pathological phosphorylation of tau [122]. Studies concerning the regulation of MARKs activity have
shown that MARK1 and MARK2 are activated by DAPK (death-associated protein kinase) and
mice brain displays a reduced phosphorylation of tau [123].
Int. J. Mol. Sci. 2014, 15 4679 PKA
Cyclic AMP (cAMP)-dependent protein kinase (PKA) is a serine/threonine protein kinase which
belongs to the non-PDPK class. PKA catalyzes tau phosphorylation in vitro and in vivo [124–126].
The phosphorylation of tau protein by PKA triggers subsequent tau phosphorylation by GSK- at
several AD-relevant phosphorylation sites (Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396
and Ser422) and simultaneously inhibits tau phosphorylation at Thr212 and Ser404. Additionally,
prephosphorylation of tau by PKA slightly promotes tau phosphorylation by cdk5 kinase at Ser396 and
inhibits its phosphorylation at Ser202, Thr212, Thr217 and Ser404 [123]. Abnormal phosphorylation
of the tau protein by PKA kinase was confirmed in vivo [127]. It has been also observed that infusion
of PKA activator, forskolin, into the lateral ventricle of brain in adult rats induced activation of PKA
by several fold and concurrently enhanced the phosphorylation of tau. TPKI and TPKII
Tau protein kinase I (TPKI) is a non-PDPK that can phosphorylate native tau isolated from normal
brain, which is already phosphorylated to some extent, but it can not phosphorylate completely
dephosphorylated tau. In contrast, TPKII can phosphorylate also the latter form of tau [128]. The tau
residues phosphorylated by TPKII were Ser202, Thr205, Ser235, and Ser404, while those by TPKI
were Ser199, Thr231, Ser396, and Ser413 [129]. Interestingly, the TPKII-dependent tau
phosphorylation increased with increasing concentration [130]. Similar interaction has been
postulated in the case of TPKI [131].
4.1.2. Tau Phosphatases
Protein phosphatases (PPs), responsible for dephosphorylation of tau include: PP2B, PP2A, PP1
and PP5 [132]. PP2B
Protein phosphatase PP2B (calcineurin) is one of the major serine/threonine phosphatases in the
brain the activity of which depends on Ca
/calmodulin. It consists of a catalytic A subunit with
molecular mass of about 63 kDa and a regulatory B subunit with molecular mass of about of 19 kDa,
which binds Ca
and shares some degree of homology with calmodulin. The results obtained using
phosphorylation-sensitive monoclonal antibodies AT-180 (against tau phosphorylated on Thr231) and
AT-270 (for Thr181) show that reduction of PP2B activity in brain by antisense oligonucleotides led to
persistent phosphorylation of tau at Thr181 and Thr231 [133]. Studies performed by Rahman et al. [134]
showed that PP2B purified from AD brains efficiently dephosphorylated p-tau. The authors found also
that the purified PP2B dephosphorylated tau obtained from AD brain at Ser199, Thr217, Ser262,
Ser396 and Ser422 with the preferential dephosphorylation at Ser262 and Ser396. Interestingly, no
significant difference in PP2B activity was found between control and AD brain in contrast to the
results obtained by Qian et al. [135] who showed a 3-fold increase in PP2B activity in AD brain as
compared to control one. The study of Kim et al. [136] concerning the PP2B phosphatase revealed
that it can catalyze dephosphorylation of the Ser9 residue on GSK-3β. The overexpression of a
Int. J. Mol. Sci. 2014, 15 4680
constitutively active PP2B mutant (A beta 1401) increased GSK-3β activity and in consequence
phosphorylation of tau. Thus, PP2B similarly to other phosphatases might also act indirectly on
tau phosphorylation. PP2A
Protein phosphatase 2A (PP2A) is a major brain tau phosphatase in vivo and thus its reduced
activity might be a factor contributing to increased tau phosphorylation [137]. PP2A contains a
catalytic C subunit, a scaffold-like A subunit and a regulatory PR55/Bα (PP2A
) subunit. By using
the NMR spectroscopy, Landrieu et al. [138] determined the dephosphorylation rates of p-tau by PP2A
and showed kinetic data for the individual sites including Ser202/Thr205 and Thr231. The authors
demonstrated the importance of the PR55/Bα regulatory subunit of PP2A in this enzymatic process,
and showed that phosphorylation at the tau Thr231 site inhibits dephosphorylation of the tau
Ser202/Thr205 sites. This effect could be released by the Pin1 isomerase. Because this Pin1 effect is
lost with the dimeric PP2A core enzyme (PP2A
) or when using a tau mutant, Thr231A that cannot be
phosphorylated at residue 231, the authors proposed that Pin1 regulates the interaction between the
PR55/Bα subunit and the Thr231 epitope on tau. Protein phosphatase PP2A also dephosphorylates tau
protein at Ser202/Thr205 in response to microtubule depolymerization [139]. Sontag et al. [140]
reported that microtubule associated protein 2 (MAP2) is dephosphorylated by endogenous PP2A/Bα
(a major PP2A holoenzyme containing PR55/Bα regulatory subunit), in the gray matter of bovine
brain. By applying in vitro binding assays, the authors showed that PP2A/Bα binds to MAP2c isoforms
through a region encompassing the microtubule-binding domain and upstream proline-rich region.
The protein-tyrosine kinase Fyn binds to the proline-rich RTPPKSP motif conserved in both MAP2
and tau and inhibits the interaction of PP2A/Bα with either tau or MAP2c. This points to a critical role
of Fyn-binding motif in MAP2 and tau in regulating signaling enzymes like PP2A/Bα and Fyn.
Dysfunction of these protein complexes is likely to contribute to tau deregulation, microtubule
disruption, and altered signaling in tauopathies. All these data, together with the observation that PP2A
is normally bound to microtubules in intact cells, suggest that the polymerization state of microtubules
could modulate the phosphorylation state of tau at specific sites in normal and AD brain. Thus one can
suggest that PP2A and its regulatory subunits might be a therapeutic target for Alzheimer’s disease. It
should be also mentioned that modulation of PP2A activity in AD brain might be due to its interaction
with an inhibitor called SET/inhibitor 2 (I2) or ARPP-19 [141–143]. PP1
Protein phosphatase 1 (PP1) plays a fundamental role in many calcium-dependent cellular processes
in neurons. Its catalytic subunit interacts with as many as 200 distinct regulatory proteins that target
PP1 to specific subcellular locations where they influence its substrate specificity [144]. PP1 requires
metal ions and its maximal activation is seen in the presence of Mn
. Dephosphorylation of
excessively phosphorylated tau obtained from AD brain by PP1 seems to be site-specific since PP1
preferentially dephosphorylated Thr212 (40%), Thr217 (26%), Ser262 (33%), Ser396 (42%) and
Ser422 (31%) [145]. Residue Thr212 was suggested to be dephosphorylated by PP1 only and not by
Int. J. Mol. Sci. 2014, 15 4681
PP2A or PP2B. This observation, although interesting, has not yet been confirmed. In other recent
studies, protein phosphatase PP1 and tau have been linked to deficits in axonal transport [146,147]. PP5
Protein phosphatase 5 (PP5) is a phosphatase ubiquitously present in different mammalian tissues
including brain, where it is abundantly expressed. Up to now, few physiological substrates of this
phosphatase have been identified. Studies performed by Liu et al. [148] showed that
dephosphorylation of p-tau by PP5 had a similar Km to that found for phosphatase PP2A and was
within the range of intraneuronal tau concentration. Phosphatase PP5 dephosphorylates tau at all 12
AD-associated abnormal phosphorylation sites studied, with different efficiency toward each site.
The most favorable sites for action of PP5 on tau are Thr205, Thr212, and Ser409, less favorable sites
being Ser199, Ser202, Ser214, Ser396 and Ser404 and the poorest site is Ser262. The activity but not
the amount of PP5 was found to be decreased by about 20% in AD neocortex which suggests that the
attenuated activity of this phosphatase might be responsible for the overphosphorylation of tau in this
disease. Recently, it has been shown that PP5 binds calcium binding proteins: S100A1, S100A2,
S100A6 or S100B and that these S100 proteins activate PP5, when checked using tau as a
physiological substrate [149]. The association of PP5 with S100 suggests a Ca
-dependent mechanism
of tau dephosphorylation. It is of note that the level of Ca
and of calcium binding proteins in most
neurodegenerative diseases, including AD, is deregulated [150]. CacyBP/SIP
Recent study [151] suggests that the calcyclin binding protein and Siah-1 interacting protein
(CacyBP/SIP) protein, dephosphorylates tau. Similar to PP5, CacyBP/SIP phosphatase activity toward
tau is affected by a calcium-binding protein, S100A6. The observed inhibition of CacyBP/SIP tau
phosphatase activity might be a result of the influence of S100A6 on the CacyBP/SIP phosphorylation
state. CacyBP/SIP is expressed in different tissues with the highest level being found in the brain.
It is mainly a neuronal protein interacting with different targets. Among them are tubulin, actin and
tropomyosin, which suggest that CacyBP/SIP might play a role in cytoskeletal reorganization.
Furthermore, dephosphorylation of tau protein [151] and of ERK1/2 kinase [152] by CacyBP/SIP
indicate that this phosphatase might play a role in signaling pathways leading to cell proliferation and
differentiation. In our study [151], we have also found that in AD patients and line 1 tau transgenic
mice, changes in cellular distribution of CacyBP/SIP were similar to those observed for two other
microtubule proteins, β-tubulin and tau. TNAP
Tau protein released on death of neurons may also induce a neurotoxic effect on hippocampal
neurons by activation of the M1 and M3 muscarinic receptors. An essential component that links both
effects is a tissue-nonspecific alkaline phosphatase (TNAP) [153]. TNAP is abundant in the central
nervous system and is mainly required to keep control over the extracellular levels of phosphorylated
compounds. TNAP dephosphorylates overphosphorylated tau once it is released upon neuronal death.
Int. J. Mol. Sci. 2014, 15 4682
Only the dephosphorylated tau behaves as an agonist of muscarinic M1 and M3 receptors, provoking a
robust and sustained intracellular calcium increase finally triggering neuronal death. An increase in
TNAP activity together with increase of protein and its transcript level were detected in AD patients.
These observations indicate that TNAP promotes the neurotoxicity of extracellular tau which
contributes to the spread of pathology in AD.
4.2. Other Post-Translational Modifications
The state of tau phosphorylation could be influenced by other post-translational modification.
The temporal sequence of glycosylation, glycation, nitration, oxidation, polyamination, sumoylation
and ubiquitination is unclear, but these modifications seem to occur before tau excessive
phosphorylation and NFTs formation [154].
Glycosylation is the covalent attachment of oligosaccharides to a protein. There are two types of
glycosylation: N-glycosylation and O-glycosylation. N- and O-glycosylation result from the attachment
of a sugar on the amine radical of asparagine on the hydroxyl radical of serine or threonine,
respectively. Protein tau can be O-GlcNAc-ylated (O-glycosylation achieved by the engraftment of
N-acetyl-glucosamine) in vitro in recombinant systems and in some transfected cell-lines in
culture [155]. In vivo, O-GlcNAc-ylation has been shown to reduce tau phosphorylation in rat cortex
and hippocampus [156]. Conversely, biochemical evidence for tau to become O-GlcNAc-ylated was
not obtained in the study of Borghgraef et al. [157] in Tau. P301L mice chronically treated with
Thiamet-G, β-N-acetyl-glucosaminidase inhibitor. In AD patients, a negative correlation has been
reported between O-GlcNAcylation level and tau phosphorylation, suggesting that O-glycosylation of
tau negatively regulates its phosphorylation [158]. Tau proteins from brains of AD patients and not
that from brains of control patients were found to be non-physiologically glycosylated. On the basis of
findings described by Takahashi et al. [159] the first step in the cascade of events leading to final tau
modification is a down-regulation of tau glycosylation which cause the conformational changes
leading to exposure of sites for their phosphorylation. The down-regulation of glycosylation and
over-activation of GSK3β, in turn facilitates abnormal tau phosphorylation.
Some evidence suggests that tau glycation prevents tau degradation and promotes its
accumulation [160]. Moreover, glycation triggers the production of free radicals amplifying oxidative
stress, which in turn increases tau phosphorylation [161]. By this mechanism, tau can be oxidized at
C322, leading to PHF assembly [69]. Furthermore, oxidative stress promotes tau nitration which
indicates that tau glycation can indirectly induce both tau oxidation and nitration, leading to tau
phosphorylation and oligomerization [162]. Polyamination promotes NFT formation [163] and,
together with tau glycation and nitration may render abnormally phosphorylated tau less prone to
biochemical degradation by ubiquitin/proteasome system [164,165]. Subsequently, tau sumoylation
can counteract ubiquitination and thus promotes tau aggregation. In this way sumoylation may control
level of aggregates of tau [166].
Int. J. Mol. Sci. 2014, 15 4683
5. Proteins Interacting with Tau
As described above, tau protein has several functions in the nerve cells. These functions are
supported by a large number of other proteins, which include proteins that affect the phosphorylation
of tau, and other proteins relevant to this modification. These proteins are discussed below.
5.1. Amyloid
Apart from showing nerve and synapse loss, the brains of patients with AD are characterized not
only by neurofibrillary tangles NFTs but also by amyloid-β (Aβ)-containing plaques. is a group of
peptides that are structurally homologous, but with different chain length, containing 3942 amino
acids. Aβ is processed from a larger amyloid precursor protein (APP) [167].
Results from both cellular and transgenic animal models indicate that tau protein is essential for
-induced neurotoxicity [168]. In the early 90s the “amyloid cascade hypothesis” was presented.
It was postulated that formation of neuritic plaques would stimulate subsequent pathological events,
including the formation of NFTs and disruption of synaptic connections, which would lead to
reduction in neurotransmission, death of tangle-bearing neurons and dementia [169].
Although and tau protein become toxic through the different mechanisms, human, animal and
in vitro studies have found a direct link between and tau in causing toxicity in AD. Ittner and
Götz [170] suggested three possible ways of interaction between both proteins: (1) drives tau
pathology; (2) synergistic toxic effects of and tau; and (3) tau may mediate toxicity. The same
authors put forward the “tau axis hypothesis” which implies that the converging point of the
pathological effects of both proteins is a dendritic area of nerve cells. The hypothesis suggests that
increased concentrations of tau within the dendrites can make neurons more vulnerable to damage
caused by Aβ in the postsynaptic dendrites [170].
There are strong experimental data indicating that tau is essential for -induced neurotoxicity.
For example, cultured hippocampal neurons from tau knock-out mice are protected against
pathology. The tau silencing in cultured hippocampal neurons from wild-type mice showed that tau
was required for pre-fibrillar Aβ-induced microtubule disassembly [168]. Also, reduction of tau
prevents Aβ-induced defects in axonal transport of mitochondria [171]. and pathological P-tau
co-localize in AD synapses [172,173]. Other studies revealed that and/or chronic oxidative stress
are critical for development of tau pathology, including tau excessive phosphorylation and NFT
formation [161,174].
5.2. Pin1
Pin1 is a peptidyl-prolyl isomerase that recognizes a specific motif of a phosphorylated serine or
threonine residue preceding a proline residue. Pin1 was first described as a nuclear protein which can
regulate a subset of mitotic and nuclear substrates, but its function is not restricted to cell cycle control
but is extended to multiple cellular processes such as transcription and apoptosis. Pin1 was shown to
be involved in tauopathies since Pin1 dysfunction may have critical consequences on tau pathological
aggregation and neuronal death [175]. Recent study performed by Kimura et al. [100] shows that Pin1
stimulates dephosphorylation of tau phosphorylated by cdk5. Pin1 binds to tau and stimulates its
Int. J. Mol. Sci. 2014, 15 4684
dephosphorylation at all cdk5 phosphorylation sites including Ser-202, Thr-205, Ser-235, and
Ser-404.Tau carrying the FTDP-17 mutation, P301L or R406W, showed slightly weaker binding to
Pin1 than wild type tau, suggesting that FTDP-17 mutations induce cdk5-dependent increased tau
phosphorylation by reducing its interaction with Pin1. These results demonstrate that mutation of
tau may change the conformation of tau, thereby suppressing dephosphorylation and potentially
contributing to the etiology of tauopathies [99,176].
Exposure of neurons to results in dephosphorylation of Pin1, its activation and
dephosphorylation of tau on Thr231. This effect might be prevented by Pin1 inhibitor or by okadaic
acid which inhibits PP2A [177]. Also, it was found that Pin1 is responsible for the transient
modulation of tau phosphorylation at Ser199, Ser396, Ser400 and Ser404 in response to [178].
Some other data suggest that Pin1 is also involved in the regulation of APP processing and
production [11]. Phosphorylation of Thr743 in APP allows Pin1 to bind to APP [179].
Thus, the observed loss in Pin1 in advanced AD is in agreement with the reported effects of Pin1 in
cellular and animal models.
5.3. Fyn Kinase
Fyn is a membrane-anchored non-receptor tyrosine kinase from the Src-family. Recent evidence
indicates the importance of tau interactions with Fyn during -mediated neurodegeneration [4,180,181].
Tau phosphorylated by Fyn on Tyr18 [182,183] has been detected in the proportion of tangles in early
AD brain [63,184]. Tau interacts with Fyn by its SH3 domain [62]. Binding of tau to SH3 domain is
regulated by phosphorylation of tau on specific serine/threonine residues [185].
Tau binds to Fyn in dendritic spines, and this interaction regulates N-methyl-D-aspartate (NMDA)
receptor signaling [4]. Pathological tau may participate in localization of Fyn in the postsynaptic
compartment, where it phosphorylates NMDA receptor subunits which leads to an increase in Ca
to excitotoxicity [186]. Ittner et al. [4] have suggested that interaction between tau and Fyn in
dendrites plays a critical role in mediating -induced neurotoxicity by influencing the stability of
complexes formed by NMDA receptor and postsynaptic density protein 95 (PSD-95). It is conceivable
that tau and Fyn might exist in a complex with NMDA receptors and PSD-95 in neurons. Activation of
signaling pathways that lead to increased activity of Fyn could therefore affect the tyrosine
phosphorylation of tau, which could potentially modulate complex formation, and result in altered
trafficking into neuronal membrane compartments. Additionally, Fyn-tau interaction plays an important
role in oligodendrocytes, where it regulates the outgrowth of cytoplasmic processes on the glial cell body.
Impairment of the tau-Fyn interaction and excessive phosphorylation of tau leads to hypomyelination of
axons [27]. All these findings suggest that tau-Fyn interaction is important for tau localization in neurons
and has significant implications during the progression of neurodegenerative diseases.
5.4. Heat Shock Proteins
Heat shock proteins, called also molecular chaperones, are highly conserved proteins. They are
involved in most aspects of protein synthesis, folding, trafficking and assembly of multiprotein
complexes [187,188].
Int. J. Mol. Sci. 2014, 15 4685
The emergence of molecular chaperones as key regulators of tau processing suggests that
conformational changes of this protein may be important events in the pathogenesis of AD and
other tauopathies. In a cellular environment, post-translational processing of tau is regulated by the
chaperone network [189].
The Hsp70 family consists of 13 proteins, some of them were first described as regulators of tau.
The most abundant proteins present in the cytoplasm are the constitutive heat shock cognate 70 protein
(Hsc70) and the inducible heat shock protein Hsp70. These two proteins share 92% homology in the
amino acid sequence. Both have highly conserved N-terminal ATPase domains and substrate-binding
domains situated just above more variable/regulatory domain [190]. Hsp70 has a dual role with tau.
It stabilizes binding of tau to microtubules as well as promoting tau degradation in combination with
chaperone-associated ubiquitin ligase (CHIP) [189]. Hsc70 and Hsp70 bind tau, but in the cytosol,
endogenous Hsc70 is more abundant than Hsp70 [190]. Recent study has demonstrated that Hsc70
regulates the association of tau with microtubules [191]. The authors found that Hsc70 facilitates
MC1 conformation, which is an epitope created when the amino acids at residues 79 interact with
residues 312–342. They speculated that tau folding into the MC1 conformation after microtubule
destabilization could be a protective mechanism to control the disordered nature of tau and prevent
self-assembly in neuron. They also found that Hsc70 enhances tau-mediated microtubule polymerization.
The work from Miyata et al. [188] has shown that inhibition of the ATPase activity of Hsp70/Hsc70
promotes proteasomal degradation of tau while its activation results in tau accumulation. Furthermore,
such inhibition was able to reduce p-tau levels and improve cognition in a transgenic mouse model.
Heat shock protein 90 (Hsp90) was also described as a tau-binding protein [192]. It has been shown
that Hsp90 promotes tau phosphorylation by its ability to regulate GSK-3β. These data may suggest
that Hsp90 allows accumulation of highly phosphorylated tau species. Additionally, other groups
report that inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two p-tau
species, p-Tau(Ser-202/Thr-205) and p-Tau(Ser-396/Ser-404) both of which are important for AD
pathogenesis [193]. Dickey et al. [194] showed that protein kinase Akt and ubiquitin ligase CHIP
co-regulate tau degradation through coordinated interactions involving Hsp90. They suggest that, by
regulation of the CHIP/Hsp90 complex, Akt reduced tau ubiquitination and slowed its degradation. In
addition, Akt enhances phosphorylation of tau at Ser262/Ser356, a site that is not recognized by the
CHIP/Hsp90 degradation complex.
5.5. FKBP51 and FKBP52 Immunophilins
In general, immunophilins are cytoplasmic proteins and their physiological function is that of a
chaperone with peptidyl-prolyl cis-/trans-isomerase (PPIase) activity. FKBP51 and FKBP52 are both
involved in tau protein turnover [195]. FKBP51 overexpression preserves tau in cells and protects it
from ubiquitination, perhaps by twisting tau in such a way as to prevent access to ubiquitin ligases.
It was also proposed that phosphorylation of tau drives the association of FKBP51 with tau, suggesting
that as tau dissociates from the microtubules, it is recognized by the chaperone machinery and primed
for dephosphorylation. FKBP51 promotes the association of tau with Hsp90 which leads to its
dephosphorylation [192] and its overexpression enhanced neuronal loss in the rTg4510 tau transgenic
mouse model [196]. FKBP51 can work with Hsp90 to produce oligomeric tau in the brain and prevent
Int. J. Mol. Sci. 2014, 15 4686
tau clearance thus increasing tau toxicity. This activity of Hsp90 in cooperation with FKBP51 is in
contrast to the effects of other chaperones that have been shown to enhance tau clearance, block
amyloid formation, and decrease tangle load in the brain.
Chambraud et al. [197] reported that FKBP52, which is abundant in brain, binds directly and
specifically to tau, especially to its highly phosphorylated form. Both proteins co-localize in the distal
part of the axons of cortical neurons where FKBP52 decreases tau ability to promote microtubule
assembly. Furthermore, overexpression of FKBP52 in differentiated PC12 cells prevented the
accumulation of tau and resulted in reduced neurite length.
5.6. α-Synuclein
α-Synuclein (α-SN) has been found in the Lewy body inclusions that are pathognomic for
Parkinson’s disease (PD). It has been suggested that α-SN may be involved in pathogenesis of
AD [198] based upon the fact that it binds to tau and primes it for action of kinases. α-Synuclein is
abundant in the brain and interacts with synaptic vesicles at presynaptic terminals. There is also
evidence for its chaperoning action for other proteins. In biochemical properties α-synuclein resembles
tau protein in several respects: it is an acidic, heat-stable, unfolded protein that has characteristic
repeats. It aggregates when it is overexpressed [199]. Recent studies show that α-synuclein has the
ability to stimulate tau phosphorylation by GSK-3β through formation of a protein complex with these
two proteins. The expression of α-SN is promoted by oxidative stress. Accumulation of α-SN induced
by such stress may lead to the excessive phosphorylation of tau by GSK-3β [200].
The studies concerning the physiological correlation between tau and α-synuclein
have also demonstrated that phosphorylated tau is present in Lewy bodies, which are
cytoplasmic inclusions formed by abnormal aggregation of α-SN. The PD-linked neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) increases the phosphorylation of tau as well as
the protein level of α-SN in cultured neuronal cells, and also in mice [200]. Other studies [201] have
shown, that α-SN interacts directly with tau and stimulates its phosphorylation by protein kinase A
(PKA). PHF-tau is phosphorylated on at least 21 sites. One of these sites, Ser262 is uniquely located
within the first microtubule-binding region of tau. Phosphorylation at this site alone was found to
detach tau from microtubules, cause microtubule instability, and make tau neurotoxic in Drosophila
and in cultured primary neurons [202]. PKA phosphorylates tau at both Ser214 and Ser262. It has been
discovered that in the presence of α-synuclein, PKA phosphorylates Ser262 to a higher extent than in
its absence. These results indicate that α-synuclein is a regulator of phosphorylation of tau at Ser262.
Phosphorylation of tau at Ser262 depends also on pathogenic mutations in α-synuclein.
5.7. PACSIN1
PACSIN1 (or SYNDAPIN1) is a neuron-specific member of the cytoplasmic adapter proteins
PACSINs family. All PACSINs represent a group of the larger Pombe Cdc15 homology (PCH) protein
family, which participate in rearrangements of actin networks during vesicle formation and
transport [203]. In their study Grimm-Günter et al. [204] have shown that PACSINs contribute to
tubulin nucleation and retard microtubule regrowth. They also suggested that other PCH proteins have
been linked with microtubule and/or centrosome function, mainly by their N-terminal F-BAR domains.
Int. J. Mol. Sci. 2014, 15 4687
Additionally, reduction of these proteins levels delay, but do not prevent, tubulin polymerization.
Neuron-specific PACSIN1 contains a highly conserved SH3 and F-BAR domain, sequence determining
PACSIN1 involvement in F-actin cytoskeleton organization and membrane trafficking [205]. PACSIN1
interacts with vesicle-associated proteins, including large GTPase DYNAMIN1 and EHD proteins, and
it plays an important role in endocytosis and endosomal recycling.
PACSIN1 was also identified by Liu et al. [205] as a tau-binding protein. PACSIN1-tau interaction
reduces tau affinity to microtubules and suppresses tau-induced microtubule polymerization, stability
and bundling. These authors used a model system of cultured dorsal root ganglia (DRG) neurons and
found that PACSIN1 blocking resulted in a higher number of straight and spread microtubules and
decreased axonal length with a greater number of primary axonal branches.
6. Tau Dysfunction
6.1. Tau Aggregates
Tau aggregates display different morphologies in different tauopathies. The type of aggregate
formed is determined by the tau isoforms involved and the presence of mutations in the tau gene [206].
In neurodegenerative diseases, such as AD and AD-related tauopathies (foldopathies) [207], tau is
highly phosphorylated and has a tighter more folded conformation and is remarkably more susceptible
to aggregate than non-phosphorylated tau [208,209]. The increased pool of soluble tau undergoes
additional conformational changes, which may support initial steps of tau assembly into
filaments [210]. Much evidence confirms that abnormal phosphorylation converts tau from a
biologically functional molecule into a toxic protein, and that this is responsible for the polymerization
of tau into paired helical filaments (PHFs), pathological structures observed in AD [211,212].
The PHFs in turn bundle into neurofibrillary tangles or neuropil threads leading to neuronal death.
Neurons accumulate misfolded protein deposits recognized by antibodies against tau of 55 to 69 kDa
and ubiquitin, and this is accompanied by PHF formation and tubulin fragmentation and
deacetylation [208,213]. The deposits tend to fill the basal pole of pyramidal neurons, encompassing
the area of the axon hillock and basal dendritic branches.
Many scientists postulated that abnormal and excessive phosphorylation precedes tau aggregation
and these aggregates are believed to be the toxic species in tauopathies. However, some experimental
evidence suggests that filamentous inclusions of tau may not be responsible for neuronal
dysfunctions [214–216]. Cowan and co-authors [217,218] have shown that highly phosphorylated
wild-type human tau causes behavioral deficits resulting from synaptic dysfunction, axonal transport
disruption, and cytoskeletal destabilization in vivo in the absence of neuronal death or filament/tangle
formation. Physiological and pathological tau species include: monomers, dimers/trimers, small
soluble oligomers, insoluble granular tau oligomers, filaments, pretangles, large non-fibrillar tau
aggregates, neurofibrillary tangles and ghost tangles [219]. There is a body of evidence, which is still
not broadly accepted, that among of all these tau species small soluble tau oligomers are the most toxic
and filamentous and fibrillar tau is neither necessary nor sufficient for tau-induced toxicity, and may
even represent a neuroprotective strategy [218–221]. Tau dimers and oligomers are considered to be
intermediates between soluble tau monomers and insoluble tau filaments. The data suggest that dimers
Int. J. Mol. Sci. 2014, 15 4688
and trimers of tau can suppress axonal transport and cause significantly greater loss of synapses
and neurons resulting in stronger memory deficits than tau monomers and fibrils [222,223].
Berger et al. [224] in rTg4510 mouse model and Sahara et al. [225] in human AD brains have shown
that tau 140-kDa dimers appeared at very early stages of disease when memory deficits were evident in
the absence of tangle formation. It has been suggested that formation of NFTs is a protective response
that ultimately fails [226] (Figure 2).
Figure 2. Proposed sequence of stages leading to tau pathology. Detachment of tau from
microtubules increases amount of misfolded tau monomers. Monomers aggregate into
small soluble tau oligomers. Small soluble tau oligomers and tau monomers can proceed to
form granular tau oligomers (GTOs). Probably both, small oligomers and GTOs form
paired helical filaments (PHFs) but GTOs are considered to be the main precursors of
PHFs. Subsequently PHFs spontaneously aggregate into neurofibrillary tangles (NFTs).
Int. J. Mol. Sci. 2014, 15 4689
6.2. Tau and Microtubule Instability
The interaction between tau and microtubules is greatly decreased by tau phosphorylation at Ser262
and Ser356 [85]. Other phosphorylation sites shown to have some effects on microtubule association
are Ser205, Ser212, Ser214, Thr231, Ser235, Ser396 and Ser404 [227–229]. However, the mechanism
leading normal tau to become overphosphorylated and disengaged from microtubules to form tau
inclusions remains unclear. Some scientists postulated that in this process reversible lysine acetylation
is engaged [68,230,231]. Since acetylation neutralizes charges in the microtubule-binding domain,
aberrant acetylation may interfere with the binding of tau to microtubule leading to tau
dysfunction [230]. Lys280, in the region
, is one of three lysine residues most
critical in modulating tau-microtubules interactions. Increase tau acetylation on Lys280, impairs the
interaction with microtubules and increases the pools of cytosolic tau available for pathological
aggregation [68].
Although most data on microtubule assembly and pathological tau have been obtained using
PHF-tau from AD patients, there is agreement that PHF-tau proteins fail to bind with
microtubules [232,233]. Abnormally phosphorylated tau isolated from brain homogenates of AD
patients (AD p-tau) comprises little overall activity, but dephosphorylation with alkaline phosphatase
recovers its normal activity to a level similar to acid-soluble tau. Microtubule assembly is inhibited in
the presence of AD p-tau while tau-tau interactions are facilitated. These studies implicate abnormal
phosphorylation of tau in the breakdown of microtubules in affected neurons in AD not only because
the altered protein has little microtubule-promoting activity but also because it interacts with normal
tau, thereby reducing the amount of “healthy” tau even further. The collapse of microtubules is
an important event of neurofibrillary degeneration induced by the aggregation of tau proteins in
nerve cells. Findings of the last studies show that interactions between tau and microtubules are
more complex than they thought. Some data [51] provide evidence that microtubules promote tau
oligomerization on their surface. Additionally Duncan and Goodson [234] have found that
microtubules induce rapid formation of tau filaments in vitro and that this process probably does not
require phosphorylation of tau. It is a question if tau filaments assembly by microtubules might play a
role in the formation of Alzheimer’s-associated PHF or NFTs in vivo.
A corollary of the abnormalities in tau-microtubule interactions is the progressive break-down of
the cytoskeleton, synaptic withdrawal [235,236], and after a brief period of survival, neuronal death
and subsequent dementia [237,238]. The cell will experience lysis so that tau is liberated into the
extracellular space. Here, tau has high affinity to molecules like sulfated glycosaminoglycans (sGAG),
which further promote its polymerization, and upon glycation of the polymers stabilize tau into
extracellular neurofibrillary tangles [239].
6.3. Tau and Neuronal Transport Defects
In postmitotic neuronal cells, one likely tau/microtubule-dependent function whose abnormality
could easily lead to neuronal cell death is axonal transport [240,241]. Indeed, several
neurodegenerative disorders are linked to disturbances in cellular cytoskeleton which controls
polarized cargo trafficking pathways in neurons [242–244].
Int. J. Mol. Sci. 2014, 15 4690
The microtubule and F-actin cytoskeleton might act as specific transport roads for intraneuronal
trafficking. In the axon and dendrites, transport occurs bidirectionally, from the cell body to the
periphery (anterograde transport) and from the periphery to the cell body (retrograde transport). These
different directions of transport depend on the polarity of the cytoskeletal tracks. Microtubules are the
polar structures: in the axon and the distal dendrites, the plus end (the fast growing end) points distally,
whereas in the proximal dendrites, the polarity is mixed [245].
Motor proteins are responsible for the intracellular transport of a wide variety of components and
for positioning them along the axon with high spatial-temporal precision. Three different classes of
motors are involved in this task: dynein and kinesin, which transport cargoes toward the minus and
plus ends of microtubules, respectively, and myosin, responsible for the transport along actin
filaments [246–248]. Members of the kinesin superfamily of proteins (KIFs) [249] are known to drive
anterograde axonal transport. Cytoplasmic dynein is the major minus end-directed microtubule motor
in the neuron and is involved in retrograde axonal transport [250].
The tau, both as microtubule stabilizing and scaffolding protein could be involved in intraneuronal
transport. Neurons containing the polar PHFs exhibit severely impaired anterograde transport along
axons as well as basal dendrites; transport in apical dendrites is also impaired but in a
retrograde-specific manner [251]. New insight into the role of axonal transport in neurodegenerative
diseases stems from the observation that proteins accumulated in AD brains can modulate kinesin-1
receptors [252,253]. Overexpression and mislocation of tau proteins appear to modulate kinesin-1
based transport [147,241] by direct inhibition of motors on microtubule tracts, and this can lead to
transport disruption for numerous cargoes, including APP vesicles, mitochondria, and peroxisomes,
which could explain the energy deprivation and the oxidative stress sensitivity of AD neurons [249,254].
Disturbance of anterograde transport of microtubules slows down exocytosis and affects the
distribution of mitochondria which become clustered near to microtubule organizing center (MTOC).
The absence of mitochondria and endoplasmic reticulum in the peripheral regions of axons cause a
decrease in glucose and lipid metabolism and ATP synthesis and loss of calcium homeostasis [16,255]
that leads to a distal degeneration process.
6.4. Tau and Neurotrophin Signaling
Since tau controls the bidirectionality of axonal motor-driven transport in a concentration-dependent
manner and differentially modulates the kinesin and dynein activity along microtubule tracks [12],
defective intracellular trafficking of cargoes, including neurotrophins, could be due to an increased
expression level of this protein [256–258] or to its altered intracellular localization [259] or
excessive phosphorylation [231,260]. To this regard, the finding that the retrograde transport of
I-125-NGF and activated TrkA receptors is inhibited by colchicine, a drug that interferes with the
polymerization of microtubules [261,262], suggests that an altered function of tau protein may account
for age-related deficiency of long-range neurotrophin signaling in cholinergic neurons. There is
good evidence that the retrograde axonal transport of the active NGF-p-TrkA complex involves
dynein [263–266], because inhibition of the dynein ATPase activity reduces the retrograde axonal
transport of exogenous
I-labelled NGF in sympathetic and sensory neurons in vivo [267].
Moreover, TrkA can directly associate with the juxtaposed membrane domain of dynein
Int. J. Mol. Sci. 2014, 15 4691
light chains [265] and phosphorylated TrkA in vesicles can attach and be transported within dynein
motors [263]. One candidate protein that is implicated in TrkA transport is a light chain of the dynein
motor complex, Tctex-1. Co-immunoprecipitation experiments from brain lysates demonstrated that
TrkA, Tctex-1, and dynein form a protein complex [268]. Functional dynein-microtubule network is
necessary for TrkA signaling to intracellular Rap1 and MAPK1/2 [269].
The hypothesis that the failure of tau-mediated axonal transport might be responsible for the lack of
trophic support in aged or AD brains [59,60,270,271] is supported by several findings. In our
study [59], we injected fluorogold (FG) into neocortex and hippocampus of young adult and 24 month
old rats and confirmed that the number of retrogradely labeled FG positive neurons was significantly
lower in subdivisions of the basal forebrain of aged rats. At the same time, tau immunostaining was
restricted to neurites in neurons of the septo-hippocampal projection in young rats, but displayed a
mainly somatodendritic distribution in aged rats. This redistribution of tau was confirmed by other
immunohistochemical markers against p-TrkA, beta-NGF, p-Tau404 and p-Tau231, and GSK-3β,
which can phosphorylate serine 404 and threonine 231 [60]. Apart from an overall lower intensity of
p-TrkA immunostaining in cortex and hippocampus of aged rats, immunoreactivity for all proteins was
high and localized to the soma in old, and to the axonal and at a somewhat lower intensity to the
dendritic compartment in young animals. Our data reveal that during aging expression of GSK-3β and
three tau protein substrates are reduced in axons and this may severely compromise the efficiency of
retrograde cytoskeletal transport.
Lazarov et al. [272] report that the anterograde fast axonal transport (FAT) of APP and Trk
receptors is impaired in the sciatic nerves of transgenic mice expressing two independent familial
Alzheimer’s disease-linked PS1 mutations. Furthermore, familial Alzheimer’s disease-linked PS1 mice
exhibit a significant increase in GSK-3β-mediated phosphorylation of the cytoskeletal proteins tau and
neurofilaments in the spinal cord, which correlate with motor neuron functional deficits. It was also
shown [273] that the loss of the N-terminal 25 amino acids of tau, which probably affects its
interaction with dynactin/dynein motor complex [274], occurs in cellular and animal models of
AD-like neurodegeneration induced by NGF signaling interruption. A crucial role of tau modifications
in NGF-dependent neuronal survival was reported by Amadoro et al. [168]. They found that an early,
transient and site-specific GSK-3β-mediated tau overphosphorylation (36 h after NGF withdrawal) at
two AD-relevant pathological epitopes (Ser262 and Thr231) is temporally and causally related with
an activation of the endogenous amyloidogenic pathway in NGF-deprived hippocampal primary
neurons [275].
7. Conclusions and Perspectives
Comprehensive investigations have revealed a role for tau protein in the neuronal cytoskeletal
collapse in aging and neurodegenerative tauopathies. Highly phosphorylated tau detaches from
microtubules and becomes retrogradely transported to the soma where it accumulates as aggregates of
tau and ultimately neurofibrillary tangles. Control of tau phosphorylation by inhibiting tau kinases
seems a feasible strategy to prevent tau aggregation and its associated pathological effects.
Tau excessive phosphorylation appears to be required, but is not sufficient alone, to induce tau
aggregation, other tau post-translational modifications are certainly required. However, tau protein
Int. J. Mol. Sci. 2014, 15 4692
regardless of its post-translational modifications, can also be toxic per se, and the suppression of tau
protein blocks Aβ-induced toxicity and reduces memory deficit. Such data suggest that reduction of
the overall tau levels may constitute a neuroprotective strategy to prevent tauopathies. Therefore,
studying tau regulation at the transcriptional and translational levels is of great interest in further
understanding of the physiological role of tau and its involvement in human pathologies.
Depletion of axonal tau protein will compromise active transport processes and, as exemplified for
cholinergic neurons, impinge on the trophic support mechanism involving NGF and its receptors. It is
worth noting that collapse of the cytoskeleton may have consequences for a number of processes.
These may include axonal and dendritic transport systems, affecting the distribution of proteins,
signaling molecules and organelles throughout the cell. Maintaining neuronal shape and contacts with
neighboring cells through synaptic afferents and efferents will also be affected. Deterioration of these
processes leads to neurodegeneration, neuronal cell death and cognitive impairment. Therefore,
prevention of tau dysfunction and maintenance of the neuronal cytoskeleton may provide important
therapeutic strategies for the treatment of AD and other tauopathies.
The authors wish to thank Charles R. Harrington from the University of Aberdeen for review and
valuable comments on the manuscript. This work has been supported by WisTa Laboratories Ltd. and
by grants from the National Science Centre to Anna Filipek (N N303 548439) and to Anna
Gasiorowska and Grazyna Niewiadomska (nr 2011/01/D/NZ7/04405), and by statutory funds from the
Nencki Institute of Experimental Biology.
Author Contributions
Each author has participated sufficiently in the work to take public responsibility for appropriate
portions of the article content.
(1) Authors who made substantial contributions to conception and design of the review: G.
Niewiadomska, A. Filipek, A. Mietelska-Porowska, M. Goras, and U. Wasik
(2) Authors who participate in drafting the article:
G. Niewiadomska—Abstract, Introduction, Paragraph 3 and 6, Conclusions, Figures 1 and 2
A. Mietelska-Porowska—Paragraphs 2, 3, and 4.2, Figures 1 and 2
U. Wasik—Paragraph 4.1.1
A. Filipek—Paragraph 4.1.2
M. Goras—Paragraph 5
(3) All Authors gave final approval of the version to be submitted and any revised version.
actin-binding proteins
Alzheimer’s disease
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
Int. J. Mol. Sci. 2014, 15 4693
adenosine-monophosphate-activated protein kinase
amyloid precursor protein
adenosine triphosphate
amyloid beta
brain-derived neurotrophic factor
calcyclin-binding protein/siah-1-interacting protein
cyclic adenosine monophosphate
corticobasal degeneration
cyclin-dependent kinase 5
chaperone-associated ubiquitin ligase CHIP
casein kinase 1
casein kinase 1
death-associated protein kinase
dorsal root ganglia
Down syndrome
dual specificity tyrosine-phosphorylation-regulated kinase 1A
exon 10
exon 2
exon 3
epidermal growth factor
Eps15 homology domain
ERK1/2 kinase
extracellular signal-regulated kinase 1/2
actin filaments
FK506-binding protein
frontotemporal dementia with parkinsonism linked to chromosome 17
Proto-oncogene tyrosine-protein kinase Fyn
gamma-aminobutyric acid
globular actin monomers
growth cones
growth factor receptor-bound protein 2
glycogen synthase kinase-3
guanosine triphosphate
Huntingtin-associated protein 1
heat shock cognate 70 protein
heat shock protein 70
Heat shock protein 90
heat shock proteins
SET/inhibitor 2
c-Jun amino-terminal kinase
kinesin proteins
voltage-gated potassium channels
muscarinic receptor 1
Int. J. Mol. Sci. 2014, 15 4694
muscarinic receptor 3
microtubule associated protein
mitogen-activated protein kinases
microtubule-associated protein tau
microtubule-affinity regulating kinases
microtubule binding domain
messenger ribonucleic acid
messenger ribonucleoprotein
microtubule organizing center
neurofilament heavy
neurofilament medium
neurofibrillary tangles
nerve growth factor
neurofilament light
N-methyl-D-aspartate receptor
NMR spectroscopy
nuclear magnetic resonance spectroscopy
non-proline-directed protein kinase
neural Wiskott-Aldrich syndrome protein
protein kinase C and casein kinase substrate in neurons protein 1
activated/phosphorylated AMPK
Pombe Cdc15 homology proteins
Parkinson’s disease
parkinsonism dementia complex of Guam
proline-directed protein kinases
paired helical filaments
Pick’s disease
peptidyl-prolyl cis-trans isomerase 1
phosphatidylinositol (3,4,5)-trisphosphate
phospho-c-Jun amino-terminal kinase
protein kinase A
protein phosphatase 1
protein phosphatase 2A
protein phosphatase 5
peptidyl-prolyl cis/trans isomerase
protein phosphatases
precursor mRNA
postsynaptic density protein 95
progressive supranuclear palsy
phosphorylated tau
Ras-related protein Rab-5A
SH3 domain
The SRC homology 3 domain
Int. J. Mol. Sci. 2014, 15 4695
proto-oncogene tyrosine-protein kinase Src
tissue-nonspecific alkaline phosphatase
tyrosine protein kinases
tau protein kinase I
tau protein kinase II
neurotrophic tyrosine kinase receptor, type 1
neurotrophic tyrosine kinase, receptor, type 2
ubiquitin proteasome system
Conflicts of Interest
The authors declare no conflict of interest.
1. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I.
Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal
pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913–4917.
2. Binder, L.I.; Frankfurter, A.; Rebhun, K.I. The distribution of tau in the mammalian central
nervous system. J. Cell Biol. 1985, 101, 1371–1378.
3. Hirokawa, N.; Funakoshi, T.; Sato-Harada, R.; Kanai, Y. Selective stabilization of tau in axons
and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized
localization of cytoskeletal proteins in mature neurons. J. Cell Biol. 1996, 132, 667–679.
4. Ittner, L.M.; Ke, Y.D.; Delerue, F.; Bi, M.; Gladbach, A.; van Eersel, J.; Wölfing, H.;
Chieng, B.C.; Christie, M.J.; Napier, I.A.; et al. Dendritic function of tau mediates amyloid-beta
toxicity in Alzheimer’s disease mouse models. Cell 2010, 142, 387–397.
5. Merino-Serrais, P.; Benavides-Piccione, R.; Blazquez-Llorca, L.; Kastanauskaite, A.;
Rábano, A.; Avila, J.; DeFelipe, J. The influence of phospho on dendritic spines of cortical
pyramidal neurons in patients with Alzheimer’s disease. Brain 2013, 136, 1913–1928.
6. Zempel, H.; Luedtke, J.; Kumar, Y.; Biernat, J.; Dawson, H.; Mandelkow, E.; Mandelkow, E.M.
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by
TTLL6 and spastin. EMBO J. 2013, 32, 2920–2937.
7. Goedert, M.; Jakes, R. Expression of separate isoforms of human tau protein: Correlation with
the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990, 9, 4225–4230.
8. Niblock, M.; Gallo, J.M. Tau alternative splicing in familial and sporadic tauopathies.
Biochem. Soc. Trans. 2012, 40, 677–680.
9. Majounie, E.; Cross, W.; Newsway, V.; Dillman, A.; Vandrovcova, J.; Morris, C.M.; Nalls, M.A.;
Ferrucci, L.; Owen, M.J.; ODonovan, M.C.; et al. Variation in tau isoform expression in
different brain regions and disease states. Neurobiol. Aging 2013, 34, 1922.e7–1922.e12.
10. Rodríguez-Martín, T.; Cuchillo-Ibáñez, I.; Noble, W.; Nyenya, F.; Anderton, B.H.; Hanger, D.P.
Tau phosphorylation affects its axonal transport and degradation. Neurobiol. Aging 2013, 34,
11. Hanger, D.P.; Anderton, B.H.; Noble, W. Tau phosphorylation: The therapeutic challenge for
neurodegenerative disease. Trends Mol. Med. 2009, 15, 112–119.
Int. J. Mol. Sci. 2014, 15 4696
12. Dixit, R.; Ross, J.L.; Goldman, Y.E.; Holzbaur, E.L. Differential regulation of dynein and
kinesin motor proteins by tau. Science 2008, 319, 1086–1089.
13. Götz, J.; Probst, A.; Spillantini, M.G.; Schäfer, T.; Jakes, R.; Bürki, K.; Goedert, M.
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice
expressing the longest human brain tau isoform. EMBO J. 1995, 14, 1304–1313.
14. Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.;
DeTure, M.; Ramsden, M.; McGowan, E.; et al. Tau suppression in a neurodegenerative mouse
model improves memory function. Science 2005, 309, 476–481.
15. Müller, W.E.; Eckert, A.; Kurz, C.; Eckert, G.P.; Leuner, K. Mitochondrial dysfunction:
Common final pathway in brain aging and Alzheimers disease—Therapeutic aspects.
Mol. Neurobiol. 2010, 41, 159–171.
16. Mondragón-Rodríguez, S.; Perry, G.; Zhu, X.; Moreira, P.I.; Acevedo-Aquino, M.C.;
Williams, S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial
dysfunction, and connectivity failure: Implications for Alzheimers disease. Oxid. Med.
Cell. Longev. 2013, 2013, 940603:1–9940603:6.
17. Hoover, B.R.; Reed, M.N.; Su, J.; Penrod, R.D.; Kotilinek, L.A.; Grant, M.K.; Pitstick, R.;
Carlson, G.A.; Lanier, L.M.; Yuan, L.L.; et al. Tau mislocalization to dendritic spines mediates
synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68, 1067–1081.
18. Prots, I.; Veber, V.; Brey, S.; Campioni, S.; Buder, K.; Riek, R.; Böhm, K.J.; Winner, B.
α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 2013, 288,
19. Eckert, A.; Nisbet, R.; Grimm, A.; Götz, J. March separate, strike togetherRole of
phosphorylated TAU in mitochondrial dysfunction in Alzheimers disease. Biochim. Biophys. Acta
2013, doi:10.1016/j.bbadis.2013.08.013.
20. Andrews-Zwilling,Y.; Bien-Ly, N.; Xu, Q.; Li, G.; Bernardo, A.; Yoon, S.; Zwilling, D.;
Yan, T.X.; Chen, L.; Huang, Y. Apolipoprotein E4 causes age- and tau-dependent impairment of
GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010, 30,
21. Gu, Y.; Oyama, F.; Ihara, Y. Tau is widely expressed in rat tissues. J. Neurochem. 1996, 67,
22. Weingarten, M.D.; Lockwood, A.H.; Hwo, S.Y.; Kirschner, M.W. A protein factor essential for
microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72, 1858–1862.
23. Witman, G.B.; Cleveland, D.W.; Weingarten, M.D.; Kirschner, M.W. Tubulin requires tau for
growth onto microtubule initiating sites. Proc. Natl. Acad. Sci. USA 1976, 73, 4070–4074.
24. Andreadis, A. Tau splicing and intricacies of dementia. J. Cell. Physiol. 2012, 227, 1120–1225.
25. Lee, V.M.; Goedert, M.; Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci.
2001, 24, 1121–1159.
26. Tashiro, K.; Hasegawa, M.; Ihara, Y.; Iwatsubo, T. Somatodendritic localization of
phosphorylated tau in neonatal and adult rat cerebral cortex. Neuroreport 1997, 8, 2797–2801.
27. Klein, C.; Kramer, E.M.; Cardine, A.M.; Schraven, B.; Brandt, R.; Trotter, J. Process outgrowth
of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau.
J. Neurosci. 2002, 22, 698–707.
Int. J. Mol. Sci. 2014, 15 4697
28. Jeganathan, S.; von Bergen, M.; Mandelkow, E.M.; Mandelkow, E. The natively unfolded
character of Tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry
2008, 47, 10526–10539.
29. Mukrasch, M.D.; Bibow, S.; Korukottu, J.; Jeganathan, S.; Biernat, J.; Griesinger, C.;
Mandelkow, E.; Zweckstetter, M. Structural polymorphism of 441-residue Tau at single residue
resolution. PLoS Biol. 2009, 7, e1000034.
30. Sergeant, N.; Bretteville, A.; Hamdane, M.; Caillet-Boudin, M.L.; Grognet, P.; Bombois, S.;
Blum, D.; Delacourte, A.; Pasquier, F.; Vanmechelen, E.; et al. Biochemistry of Tau in
Alzheimer’s disease and related neurological disorders. Exp. Rev. Proteomics 2008, 5, 207–224.
31. Mandelkow, E.M.; Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary
degeneration. Cold Spring Harb. Perspect. Med. 2012, 2, a006247.
32. Steiner, B.; Mandelkow, E.M.; Biernat, J.; Gustke, N.; Meyer, H.E.; Schmidt, B.; Mieskes, G.;
Soling, H.D.; Drechsel, D.; Kirschner, M.W. Phosphorylation of microtubule-associated protein
tau: Identification of the site for Ca2(þ)-calmodulin dependent kinase and relationship with tau
phosphorylation in Alzheimer tangles. EMBO J. 1990, 9, 3539–3544.
33. Brandt, R.; Lee, G. Functional organization of microtubule-associated protein tau. Identification of
regions which affect microtubule growth, nucleation, and bundle formation in vitro. J. Biol. Chem.
1993, 268, 3414–3419.
34. Sontag, E.; Nunbhakdi-Craig, V.; Lee, G.; Brandt, R.; Kamibayashi, C.; Kuret, J.;
White, C.L., 3rd.; Mumby, M.C.; Bloom, G.S. Molecular interactions among protein
phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation
and the development of tauopathies. J. Biol. Chem. 1999, 274, 25490–25498.
35. Hirokawa, N.; Shiomura, Y.; Okabe, S. Tau proteins: The molecular structure and mode of
binding on microtubules. J. Cell Biol. 1988, 107, 1449–1459.
36. Jung, D.; Filliol, D.; Miehe, M.; Rendon, A. Interaction of brain mitochondria with microtubules
reconstituted from brain tubulin and MAP2 or TAU. Cell Motil. Cytoskeleton 1993, 24,
37. Brandt, R.; Léger, J.; Lee, G. Interaction of tau with the neural plasma membrane mediated by
tau’s amino-terminal projection domain. J. Cell Biol. 1995, 131, 1327–1340.
38. Al-Bassam, J.; Ozer, R.S.; Safer, D.; Halpain, S.; and Milligan, R.A. MAP2 and tau bind
longitudinally along the outer ridges of microtubule protofilaments. J. Cell Biol. 2002, 157,
39. Sergeant, N.; Delacourte, A.; Buée, L. Tau protein as a differential biomarker of tauopathies.
Biochim. Biophys. Acta 2005, 1739, 17915hi.
40. Georgieff, I.S.; Liem, R.K.H.; Couchie, D.; Mavilia, C.; Nunez, J.; Shelanski, M.L.
Expression of high molecular weight tau in the central and peripheral nervous systems.
J. Cell Sci. 1993, 105, 729–737.
41. Wang, J.Z.; Liu, F. Microtubule-associated protein tau in development, degeneration and
protection of neurons. Prog. Neurobiol. 2008, 85, 148–175.
42. Morfini, G.A.; Burns, M.; Binder, L.I.; Kanaan, N.M.; LaPointe, N.; Bosco, D.A.; Brown, R.H., Jr.;
Brown, H.; Tiwari, A.; Hayward, L.; et al. Axonal transport defects in neurodegenerative
diseases. J. Neurosci. 2009, 29, 12776–12786.
Int. J. Mol. Sci. 2014, 15 4698
43. Kosik, K.S. The molecular and cellular biology of tau. Brain Pathol. 1993, 3, 39–43.
44. Jho, Y.S.; Zhulina, E.B.; Kim, M.W.; Pincus, P.A. Monte carlo simulations of tau proteins:
Effect of phosphorylation. Biophys. J. 2010, 99, 2387–2397.
45. Fischer, D.; Mukrasch, M.D.; Biernat, J.; Bibow, S.; Blackledge, M.; Griesinger, C.;
Mandelkow, E.; Zweckstetter, M. Conformational changes specific for pseudophosphorylation at
serine 262 selectively impair binding of tau to microtubules. Biochemistry 2009, 48,
46. Avila, J. Tau kinases and phosphatases: Commentary. J. Cell. Mol. Med. 2008, 12, 258–259.
47. Dolan, P.J.; Johnson G.V. The role of tau kinases in Alzheimer’s disease. Curr. Opin. Drug
Discov. Devel. 2010, 13, 595–603.
48. Gustke, N.; Trinczek, B.; Biernat, J.; Mandelkow, E.M.; Mandelkow, E. Domains of tau protein
and interactions with microtubules. Biochemistry 1994, 33, 9511–9522.
49. Seitz, A.; Kojima, H.; Oiwa, K.; Mandelkow, E.M.; Song, Y.H.; Mandelkow, E. Single-molecule
investigation of the interference between kinesin, tau and MAP2c. EMBO J. 2002, 21, 48964905.
50. Mukrasch, M.D.; von Bergen, M.; Biernat, J.; Fischer, D.; Griesinger, C.; Mandelkow, E.;
Zweckstetter, M. The “jaws” of the tau-microtubule interaction. J. Biol. Chem. 2007, 282,
51. Sillen, A.; Barbier, P.; Landrieu, I.; Lefebvre, S.; Wieruszeski, J.M.; Leroy, A.; Peyrot, V.;
Lippens, G. NMR investigation of the interaction between the neuronal protein tau and the
microtubules. Biochemistry 2007, 46, 3055–3064.
52. Panda, D.; Samuel, J.C.; Massie, M.; Feinstein, S.C.; Wilson, L. Differential regulation of
microtubule dynamics by three- and four-repeat tau: Implications for the onset of
neurodegenerative disease. Proc. Nat. Acad. Sci. USA 2003, 100, 9548–9553.
53. Santarella, R.A.; Skiniotis, G.; Goldie, K.N.; Tittmann, P.; Gross, H.; Mandelkow, E.M.;
Mandelkow, E.; Hoenger, A. Surface-decoration of microtubules by human tau. J. Mol. Biol.
2004, 339, 539–553.
54. Mandell, J.W.; Banker, G.A. A spatial gradient of tau protein phosphorylation in nascent axons.
J. Neurosci. 1996, 16, 5727–5740.
55. Yu, J.Z.; Rasenick, M.M. Tau associates with actin in differentiating PC12 cells. FASEB J. 2006,
20, 1452–1461.
56. He, H.J.; Wang, X.S.; Pan, R.; Wang, D.L.; Liu, M.N.; He, R.Q. The proline-rich domain of tau
plays a role in interactions with actin. BMC Cell Biol. 2009, 10, 81.
57. Farias, G.A.; Muñoz, J.P.; Garrido, J.; Maccioni, R.B. Tubulin, actin, and tau protein interactions
and the study of their macromolecular assemblies. J. Cell. Biochem. 2002, 85, 315–324.
58. Sharma, V.M.; Litersky, J.M.; Bhaskar, K.; Lee, G. Tau impacts on growth-factor-stimulated
actin remodeling. J. Cell Sci. 2007, 120, 748–757.
59. Niewiadomska, G.; Baksalerska-Pazera, M.; Riedel, G. Altered cellular distribution of
phospho-tau proteins coincides with impaired retrograde axonal transport in neurons of aged rats.
Ann. N. Y. Acad. Sci. 2005, 1048, 287–295.
60. Niewiadomska, G.; Baksalerska-Pazera, M.; Lenarcik, I.; Riedel, G.J, Compartmental protein
expression of Tau, GSK-3beta and TrkA in cholinergic neurons of aged rats. J. Neural Transm.
2006, 113, 1733–1746.
Int. J. Mol. Sci. 2014, 15 4699
61. Leugers, C.J.; Lee, G. Tau potentiates nerve growth factor-induced mitogen-activated protein
kinase signaling and neurite initiation without a requirement for microtubule binding.
J. Biol. Chem. 2010, 285, 19125–19134.
62. Reynolds, C.H.; Garwood, C.J.; Wray, S.; Price, C.; Kellie, S.; Perera, T.; Zvelebil, M.;
Yang, A.; Sheppard, P.W.; Varndell, I.M.; et al. Phosphorylation regulates tau interactions with
Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and
Src family kinases. J. Biol. Chem. 2008, 283, 18177–18186.
63. Lee, G.; Thangvel, R.; Sharma, V.M.; Litersky, J.M.; Bhaskar, K.; Fang, S.M.; Do, L.H.;
Andreadis, A.; van Hoesen, G.; Ksiezak-Reding, H. Phosphorylation of tau by fyn: Implications
for Alzheimer’s disease. J. Neurosci. 2004, 4, 2304–2312.
64. Miyasaka, T.; Watanabe, A.; Saito, Y.; Murayama, S.; Mann, D.M.; Yamazaki, M.; Ravid, R.;
Morishima-Kawashima, M.; Nagashima, K.; Ihara, Y. Visualization of newly deposited tau in
neurofibrillary tangles and neuropil threads. J. Neuropathol. Exp. Neurol. 2005, 64, 665–674.
65. Ledesma, M.D.; Bonay, P.; Colaço, C.; Avila, J. Analysis of microtubule-associated protein tau
glycation in paired helical filaments. J. Biol. Chem. 1994, 269, 21614–21619.
66. Reyes, J.F.; Reynolds, M.R.; Horowitz, P.M.; Fu, Y.; Guillozet-Bongaarts, A.L.; Berry, R.;
Binder, L.I. A possible link between astrocyte activation and tau nitration in Alzheimer’s disease.
Neurobiol. Dis. 2008, 31, 198–208.
67. Arnold, C.S.; Johnson, G.V.; Cole, R.N.; Dong, D.L.; Lee, M.; Hart, G.W.
The microtubule-associated protein tau is extensiveely modified with O-linked
N-acetylglucosamine. J. Biol. Chem. 1996, 271, 28741–28744.
68. Cohen, T.J.; Guo, J.L.; Hurtado, D.E.; Kwong, L.K.; Mills, I.P.; Trojanowski, J.Q.; Lee, V.M.
The acetylation of tau inhibits its function and promotes pathological tau aggregation.
Nat. Commun. 2011, 2, 252.
69. Landino, L.M.; Skreslet, T.E.; Alston, J.A. Cysteine oxidation of tau and microtubule-associated
protein-2 by peroxynitrite: Modulation of microtubule assembly kinetics by the thioredoxin
reductase system. J. Biol. Chem. 2004, 279, 35101–35105.
70. Wilhelmus, M.M.; Grunberg, S.C.; Bol, J.G.; van Dam, A.M.; Hoozemans, J.J.;
Rozemuller, A.J.; Drukarch, B. Transglutaminases and transglutaminase-catalyzed cross-links
colocalize with the pathological lesions in Alzheimer’s disease brain. Brain Pathol. 2009, 19,
71. Dorval, V.; Fraser P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded
proteins tau and alpha-synuclein. J. Biol. Chem. 2006, 281, 9919–9924.
72. Cripps, D.; Thomas, S.N.; Jeng, Y.; Yang, F.; Davies, P.; Yang, A.J. Alzheimer disease-specific
conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through
Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J. Biol. Chem. 2006, 281, 10825–10838.
73. Mondragón-Rodríguez, S.; Basurto-Islas, G.; Binder, L.I.; García-Sierra, F. Conformational
changes and cleavage; are these responsible for the tau aggregation in Alzheimer’s disease?
Futur. Neurol. 2009, 4, 39–53.
Int. J. Mol. Sci. 2014, 15 4700
74. Bhat, R.V.; Shanley, J.; Correll, M.P.; Fieles, W.E.; Keith, R.A.; Scott, C.W.; Lee, C.M.
Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in
cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA 2000, 26,
75. Wang, Q.M.; Fiol, C.J.; DePaoli-Roach, A.A.; Roach, P.J. Glycogen synthase kinase-3 beta is a
dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.
J. Biol. Chem. 1994, 269, 14566–14574.
76. Giese, K.P. GSK-3: A key player in neurodegeneration and memory. IUBMB Life 2009, 61,
77. Ishiguro, K.; Shiratsuchi, A.; Sato, S.; Omori, A.; Arioka, M.; Kobayashi, S.; Uchida, T.;
Imahori, K. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several
epitopes of paired helical filaments. FEBS Lett. 1993, 325, 167–172.
78. Lovestone, S.; Reynolds, C.H.; Latimer, D.; Davis, D.R.; Anderton, B.H.; Gallo, J.M.;
Hanger, D.; Mulot, S.; Marquardt, B.; Stabel, S.; et al. Alzheimer disease-like phosphorylation of
the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian
cells. Curr. Biol. 1994, 4, 1077–1086.
79. Reynolds, C.H.; Betts, J.C.; Blackstock, W.P.; Nebreda, A.R.; Anderton, B.H. Phosphorylation
sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the
mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen
synthase kinase-3beta. J. Neurochem. 2000, 74, 1587–1595.
80. Pei, J.J.; Tanaka, T.; Tung, Y.C.; Braak, E.; Iqbal, K.; Grundke-Iqbal, I. Distribution, levels, and
activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol.
1997, 56, 70–78.
81. Leroy, K.; Boutajangout, A.; Authelet, M.; Woodgett, J.R.; Anderton, B.H.; Brion, J.P. The
active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in
neurons in Alzheimers’s disease. Acta Neuropathol. 2002, 103, 91–99.
82. Yamaguchi, H.; Ishiguro, K.; Uchida, T.; Takashima, A.; Lemere, C.A.; Imahori, K. Preferential
labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK)
I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II.
Acta Neuropathol. 1996, 92, 232–241.
83. Alvarez, G.; Munoz-Montano, J.R.; Satrustegui, J.; Avila, J.; Bogonez, E.; Diaz-Nido, J.
Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett.
1999, 453, 260–264.
84. Tan, W.F.; Cao, X.Z.; Wang, J.K.; Lv, H.W.; Wu, B.Y. Protective effects of lithium treatment
for spatial memory deficits induced by tau hyperphosphorylation in splenectomized rats.
Clin. Exp. Pharmacol. Physiol. 2010, 37, 1010–1015.
85. Biernat. J.; Gustke, N.; Drewes, G.; Mandelkow, E.M.; Mandelkow, E. Phosphorylation of
Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like
immunoreactivity and microtubule binding. Neuron 1993, 11, 153–156.
86. Muntané, G.; Dalfó, E.; Martinez, A.; Ferrer, I. Phosphorylation of tau and alpha-synuclein in
synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s
disease and related alpha-synucleinopathies. Neuroscience 2008, 152, 913–923.
Int. J. Mol. Sci. 2014, 15 4701
87. Gaig, C.; Ezquerra, M.; Marti, M.J.; Valldeoriola, F.; Muñoz, E.; Lladó, A.; Rey, M.J.;
Cardozo, A.; Molinuevo, J.L.; Tolosa, E. Screening for the LRRK2 G2019S and codon-1441
mutations in a pathological series of Parkinsonian syndromes and frontotemporal lobar
degeneration. J. Neurol. Sci. 2008, 270, 94e8.
88. Wang, Y.; Liu, W.; He, X.; Zhou, F. Parkinsons Disease-Associated Dj-1 Mutations increase
abnormal phosphorylation of Tau protein through Akt/Gsk-pathways. J. Mol. Neurosci. 2013,
51, 911–918.
89. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.;
LaFrancois, J.; Feinstein, B.; et al. Inhibition of glycogen synthase kinase-3 by lithium correlates
with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA 2005, 102,
90. Köhler, C.; Dinekov, M.; Götz, J. Active glycogen synthase kinase-3 and tau pathology-related
tyrosine phosphorylation in pR5 human tau transgenic mice. Neurobiol. Aging 2013, 34, 13691379.
91. Dhavan, R.; Tsai, L.H. A decade of CDK5. Nat. Rev. Mol. Cell. Biol. 2001, 2, 749–759.
92. Lee, M.S.; Kwon, Y.T.; Li, M.; Peng, J.; Friedlander, R.M.; Tsai, L.H. Neurotoxicity induces
cleavage of p35 to p25 by calpain. Nature 2000, 405, 360–364.
93. Noble, W.; Olm, V.; Takata, K.; Casey, E.; Mary, O.; Meyerson, J.; Gaynor, K.; LaFrancois, J.;
Wang, L.; Kondo, T.; et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo.
Neuron 2003, 38, 555–565.
94. Cruz, J.C.; Tseng, H.C.; Goldman, J.A.; Shih, H.; Tsai, L.H. Aberrant Cdk5 activation by p25
triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron
2003, 30, 471–83.
95. Patrick, G.N.; Zukerberg, L.; Nikolic, M.; de la Monte, S.; Dikkes, P.; Tsai, L.H. Conversion of
p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402,
96. Piedrahita, D.; Hernández, I.; López-Tobón, A.; Fedorov, D.; Obara, B.; Manjunath, B.S.;
Boudreau, R.L.; Davidson, B.; Laferla, F.; Gallego-Gómez, J.C.; et al. Silencing of CDK5
reduces neurofibrillary tangles in transgenic Alzheimer mice. J. Neurosci. 2010, 30,
97. Li, T.; Hawkes, C.; Qureshi, H.Y.; Kar, S.; Paudel, H.K. Cyclin-dependent protein kinase 5
primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta.
Biochemistry 2006, 45, 3134–3145.
98. Liou, Y.C.; Sun, A.; Ryo, A.; Zhou, X.Z.; Yu, Z.X.; Huang, H.K.; Uchida, T.; Bronson, R.;
Bing, G.; Li, X.; et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent
neurodegeneration. Nature 2003, 424, 556–61.
99. Yotsumoto, K.; Saito, T.; Asada, A.; Oikawa, T.; Kimura, T.; Uchida, C.; Ishiguro, K.;
Uchida, T.; Hasegawa, M.; Hisanaga, S. Effect of Pin1 or microtubule binding on
dephosphorylation of FTDP-17 mutant Tau. J. Biol. Chem. 2009, 284, 16840–16847.
100. Kimura, T.; Tsutsumi, K.; Taoka, M.; Saito, T.; Masuda-Suzukake, M.; Ishiguro, K.; Plattner, F.;
Uchida, T.; Isobe, T.; Hasegawa, M.; et al. Isomerase Pin1 stimulates dephosphorylation of tau
protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.
J. Biol. Chem. 2013, 288, 7968–7977.
Int. J. Mol. Sci. 2014, 15 4702
101. Ferrer, I.; Blanco, R.; Carmona, M.; Puig, B. Phosphorylated mitogen-activated protein kinase
(MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase
(SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially
expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural Transm. 2001, 108,
102. Mohit, A.A.; Martin, J.H.; Miller, C.A. p493F12 kinase: A novel MAP kinase expressed in a
subset of neurons in the human nervous system. Neuron 1995, 14, 67–78.
103. Zhu, X.; Raina, A.K.; Rottkamp, C.A.; Aliev, G.; Perry, G.; Boux, H.; Smith, M.A. Activation
and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating
neurons in Alzheimer disease. J. Neurochem. 2001, 76, 435–441.
104. Knippschild, U.; Gocht, A.; Wolff, S.; Huber, N.; Löhler, J.; Stöter, M. The casein kinase 1
family: Participation in multiple cellular processes in eukaryotes. Cell. Signal. 2005, 17,
105. Singh, T.J.; Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of tau protein by casein kinase-1
converts it to an abnormal Alzheimer-like state. J. Neurochem. 1995, 64, 1420–1423.
106. Kuret, J.; Johnson, G.S.; Cha, D.; Christenson, E.R.; DeMaggio, A.J.; Hoekstra, M.F.
Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer
disease brain. J. Neurochem. 1997, 69, 2506–2515.
107. Li, G.; Yin, H.; Kuret, J. Casein kinase 1 delta phosphorylates tau and disrupts its binding to
microtubules. J. Biol. Chem. 2004, 279, 15938–15945.
108. Schwab, C.; DeMaggio, A.J.; Ghoshal, N.; Binder, L.I.; Kuret, J.; McGeer, P.L. Casein kinase 1
delta is associated with pathological accumulation of tau in several neurodegenerative diseases.
Neurobiol. Aging 2000, 21, 503–510.
109. Yasojima, K.; Kuret, J.; DeMaggio, A.J.; McGeer, E.; McGeer, P.L. Casein kinase 1 delta
mRNA is upregulated in Alzheimer disease brain. Brain Res. 2000, 865, 116–120.
110. Ferrer, I.; Barrachina, M.; Puig, B.; Martínez de Lagrán, M.; Martí, E.; Avila, J.; Dierssen, M.
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome,
Pick disease, and related transgenic models. Neurobiol. Dis. 2005, 20, 392–400.
111. Liu, F.; Liang, Z.; Wegiel, J.; Hwang, Y.W.; Iqbal, K.; Grundke-Iqbal, I.; Ramakrishna, N.;
Gong, C.X. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down
syndrome. FASEB J. 2008, 22, 3224–3233.
112. Ryoo, S.R.; Jeong, H.K.; Radnaabazar, C.; Yoo, J.J.; Cho, H.J.; Lee, H.W.; Kim, I.S.; Cheon, Y.H.;
Ahn, Y.S.; Chung, S.H.; et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link
between Down syndrome and Alzheimer disease. J. Biol. Chem. 2007, 282, 34850–34857.
113. Wegiel, J.; Kaczmarski, W.; Barua, M.; Kuchna, I.; Nowicki, K.; Wang, K.C.; Wegiel, J.;
Yang, S.M.; Frackowiak, J.; Mazur-Kolecka, B.; et al. Link between DYRK1A overexpression
and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down
syndrome. J. Neuropathol. Exp. Neurol. 2011, 70, 36–50.
114. Vingtdeux, V.; Davies, P.; Dickson, D.W.; Marambaud, P. AMPK is abnormally activated in
tangle- and pre-tangle-bearing neurons in Alzheimer disease and other tauopathies.
Acta Neuropathol. 2011, 121, 337–349.
Int. J. Mol. Sci. 2014, 15 4703
115. Thornton, C.; Bright, N.J.; Sastre, M.; Muckett, P.J.; Carling, D. AMP-activated protein kinase
(AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem. J. 2011,
434, 503–512.
116. Timm, T.; Marx, A.; Panneerselvam, S.; Mandelkow, E.; Mandelkow, E.M. Structure and
regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein.
BMC Neurosci. 2008, 2, S9.
117. Chin, J.Y.; Knowles, R.B.; Schneider, A.; Drewes, G.; Mandelkow, E.M.; Hyman, B.T.
Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles
in Alzheimer brain: A fluorescence resonance energy transfer study. J. Neuropathol. Exp. Neurol.
2000, 59, 966–971.
118. Gustke, N.; Steiner, B.; Mandelkow, E.M.; Biernat, J.; Meyer, H.E.; Goedert, M.; Mandelkow, E.
The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves
Ser-Pro and Thr-Pro motifs. FEBS Lett. 1992, 307, 199–205.
119. Augustinack, J.C.; Sanders, J.L.; Tsai, L.H.; Hyman, B.T. Colocalization and fluorescence
resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary
tangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 2002, 61, 557–564.
120. Augustinack, J.C.; Schneider, A.; Mandelkow, E.M.; Hyman, B.T. Specific tau phosphorylation
sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol.
2002, 103, 26–35.
121. Mocanu, M.M.; Nissen, A.; Eckermann, K.; Khlistunova, I.; Biernat, J.; Drexler, D.; Petrova, O.;
Schönig, K.; Bujard, H.; Mandelkow, E.; et al. The potential for beta-structure in the repeat
domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly
with endogenous Tau in inducible mouse models of tauopathy. J. Neurosci. 2008, 28, 737–748.
122. Gu, G.J.; Lund, H.; Wu, D.; Blokzijl, A.; Classon, C.; von Euler, G.; Landegren, U.;
Sunnemark, D.; Kamali-Moghaddam, M. Role of individual MARK isoforms in phosphorylation
of tau at Ser262 in Alzheimer disease. Neuromol. Med. 2013, 15, 458–469.
123. Wu, P.R.; Tsai, P.I.; Chen, G.C.; Chou, H.J.; Huang, Y.P.; Chen, Y.H.; Lin, M.Y.; Kimchi, A.;
Chien, C.T.; Chen, R.H. DAPK activates MARK1/2 to regulate microtubule assembly, neuronal
differentiation, and tau toxicity. Cell Death Differ. 2011, 18, 1507–1520.
124. Sun, L.; Wang, X.; Liu, S.; Wang, Q.; Wang, J.; Bennecib, M.; Gong, C.X.; Sengupta, A.;
Grundke-Iqbal, I.; Iqbal, K. Bilateral injection of isoproterenol into hippocampus induces
Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat. FEBS Lett. 2005,
579, 251–258.
125. Liu, F.; Liang, Z.; Shi, J.; Yin, D.; El-Akkad, E.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X.
PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and
kinase-specific manners. FEBS Lett. 2006, 580, 6269–6274.
126. Liu, F.; Li, B.; Tung, E.J.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Site-specific effects of tau
phosphorylation on its microtubule assembly activity and self-aggregation. Eur. J. Neurosci.
2007, 26, 3429–3436.
127. Liu, S.J.; Zhang, J.Y.; Li, H.L.; Fang, Z.Y., Wang, Q.; Deng, H.M.; Gong, C.X.; Grundke-Iqbal, I.;
Iqbal, K.; Wang, J.Z. Tau becomes a more favorable substrate for GSK-3 when it is
prephosphorylated by PKA in rat brain. J. Biol. Chem. 2004, 279, 50078–50088.
Int. J. Mol. Sci. 2014, 15 4704
128. Arioka, M.; Tsukamoto, M.; Ishiguro, K.; Kato, R.; Sato, K.; Imahori, K.; Uchida, T. Tau protein
kinase II is involved in the regulation of the normal phosphorylation state of tau protein.
J. Neurochem. 1993, 60, 461–468.
129. Imahori, K.; Hoshi, M.; Ishiguro, K.; Sato, K.; Takahashi, M.; Shiurba. R.; Yamaguchi. H.;
Takashima, A.; Uchida, T. Possible role of tau protein kinases in pathogenesis of Alzheimer
disease. Neurobiol. Aging 1998, 19, S93–S98.
130. Rank, K.B.; Pauley, A.M.; Bhattacharya, K.; Wang, Z.; Evans, D.B.; Fleck, T.J.; Johnston, J.A.;
Sharma, S.K. Direct interaction of soluble human recombinant tau protein with Abeta 1–42
results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett. 2002,
514, 263–268.
131. Takashima, A.; Honda, T.; Yasutake, K.; Michel, G.; Murayama, O.; Murayama, M.;
Ishiguro, K.; Yamaguchi, H. Activation of tau protein kinase I/glycogen synthase kinase-3beta
by amyloid beta peptide (2535) enhances phosphorylation of tau in hippocampal neurons.
Neurosci. Res. 1998, 31, 317–323.
132. Braithwaite, S.P.; Stock, J.B.; Lombroso, P.J.; Nairn, A.C. Protein phosphatases and Alzheimer’s
disease. Prog. Mol. Biol. Transl. Sci. 2012, 106, 343–379.
133. Garver, T.D.; Kincaid, R.L.; Conn, R.A.; Billingsley, M.L. Reduction of calcineurin activity in
brain by antisense oligonucleotides leads to persistent phosphorylation of tau protein at Thr181
and Thr231. Mol. Pharmacol. 1999, 55, 632–641.
134. Rahman, A.; Grundke-Iqbal, I.; Iqbal, K. PP2B isolated from human brain preferentially
dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally
hyperphosphorylated tau. J. Neural Transm. 2006, 113, 219–230.
135. Qian, W.; Yin, X.; Hu, W.; Sh, J.; Gu, J.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X.; Liu, F.
Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer’s disease.
J. Alzheimers Dis. 2011, 23, 617–627.
136. Kim, Y.; Lee, Y.I.; Seo, M.; Kim, S.Y.; Lee, J.E.; Youn, H.D.; Kim, Y.S.; Juhnn, Y.S.
Calcineurin dephosphorylates glycogen synthase kinase-3 beta at serine-9 in neuroblast-derived
cells. J. Neurochem. 2009, 111, 344–354.
137. Iqbal, K.; Alonso, A.C.; Chen, S.; Chohan, M.O.; El-Akkad, E.; Gong, C.X., Khatoon, S.; Li, B.;
Liu, F.; Rahman, A.; et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim.
Biophys. Acta 2005, 1739, 198–210.
138. Landrieu, I.; Smet-Nocca, C.; Amniai, L.; Louis, J.V.; Wieruszeski, J.M.; Goris, J.; Janssens, V.;
Lippens, G. Molecular implication of PP2A and Pin1 in the Alzheimer’s disease specific
hyperphosphorylation of Tau. PLoS One 2011, 6, e21521.
139. Merrick, S.E.; Demoise, D.C.; Lee, V.M. Site-specific dephosphorylation of tau protein at
Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves
protein phosphatase 2A. J. Biol. Chem. 1996, 271, 5589–5594.
140. Sontag, J.M.; Nunbhakdi-Craig, V.; White, C.L., 3rd; Halpain, S.; Sontag, E. The protein
phosphatase PP2A/Balpha binds to the microtubule-associated proteins Tau and MAP2 at a motif
also recognized by the kinase Fyn: Implications for tauopathies. J. Biol. Chem. 2012, 287,
Int. J. Mol. Sci. 2014, 15 4705
141. Tanimukai, H.; Grundke-Iqbal, I.; Iqbal, K. Up-regulation of inhibitors of protein
phosphatase-2A in Alzheimer’s disease. Am. J. Pathol. 2005, 166, 1761–1771.
142. Gharbi-Ayachi, A.; Labbe, J.C.; Burgess, A.; Vigneron, S.; Strub, J.M.; Brioudes, E.;
van-Dorsselaer, A.; Castro, A.; Lorca, T. The substrate of Greatwall kinase, Arpp 19, controls
mitosis by inhibiting protein phosphatase 2A. Science 2010, 330, 1673–1677.
143. Mochida, S.; Maslen, S.L.; Skehel, M.; Hunt, T. Greatwall phosphorylates an inhibitor of protein
phosphatase 2A that is essential for mitosis. Science 2010, 330, 1670–1673.
144. Bollen, M. Combinatorial control of protein phosphatase-1. Trends Biochem. Sci. 2001, 26,
145. Rahman, A.; Grundke-Iqbal, I.; Iqbal, K. Phosphothreonine-212 of Alzheimer abnormally
hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem. Res.
2005, 30, 277–287.
146. Lapointe, N.E.; Morfini, G.; Pigino, G.; Gaisina, I.N.; Kozikowski, A.P.; Binder, L.I.;
Brady, S.T. The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications
for filament toxicity. J. Neurosci. Res. 2009, 87, 440–451.
147. Kanaan, N.M.; Morfini, G.A.; Lapointe, N.E.; Pigino, G.F.; Patterson, K.R.; Song, Y.;
Andreadis, A.; Fu, Y.; Brady, S.T.; Binder, L.I. Pathogenic forms of tau inhibit
kinesin-dependent axonal transport through a mechanism involving activation of axonal
phosphotransferases. J. Neurosci. 2011, 31, 9858–9868.
148. Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Rossie, S.; Gong, C.X. Dephosphorylation of tau by protein
phosphatase 5: Impairment in Alzheimer’s disease. J. Biol. Chem. 2005, 280, 1790–1796.
149. Yamaguchi, F.; Umeda, Y.; Shimamoto, S.; Tsuchiya, M.; Tokumitsu, H.; Tokuda, M.;
Kobayashi, R. S100 Proteins Modulate Protein Phosphatase 5 Function: A link between Ca
signal transduction and protein dephosphorylation. J. Biol. Chem. 2012, 287, 13787–13798.
150. Fedrizzi, L.; Carafoli, E. Ca
dysfunction in neurodegenerative disorders: Alzheimer’s disease.
Biofactors 2011, 37, 189–196.
151. Wasik, U.; Schneider, G.; Mietelska-Porowska, A.; Mazurkiewicz, M.; Fabczak, H.; Weis, S.;
Zabke, C.; Harrington, C.R.; Filipek, A.; Niewiadomska, G. Calcyclin binding protein and Siah-1
interacting protein in Alzheimer’s disease pathology: Neuronal localization and possible
function. Neurobiol. Aging 2013, 34, 1380–1388.
152. Kilanczyk, E.; Filipek, S.; Filipek, A. ERK1/2 is dephosphorylated by a novel phosphatase
CacyBP/SIP. Biochem. Biophys. Res. Commun. 2011, 404, 179–183.
153. Diaz-Hernandez, M.; Gomez-Ramos, A.; Rubio, A.; Gomez-Villafuertes, R.; Naranjo, J.R.;
Miras-Portugal, M.T.; Avila, J. Tissue-nonspecific alkaline phosphatase promotes the
neurotoxicity effect of extracellular tau. J. Biol. Chem. 2010, 285, 32539–32548.
154. Necula, M.; Kuret, J. Pseudophosphorylation and glycation of tau protein enhance but do not
trigger fibrillization in vitro. J. Biol. Chem. 2004, 279, 49694– 49703.
155. Smet-Nocca, C.; Broncel, M.; Wieruszeski, J.M.; Tokarski, C.; Hanoulle, X.; Leroy, A.;
Landrieu, I.; Rolando, C.; Lippensa, G.; Hackenberger, C.P.R. Identification of O-GlcNAc sites
within peptides of the Tau protein and their impact on phosphorylation. Mol. BioSyst. 2011, 7,
Int. J. Mol. Sci. 2014, 15 4706
156. Yuzwa, S.A.; Macauley, M.S.; Heinonen, J.E.; Shan, X.; Dennis, R.J.; He, Y.; Whitworth, G.E.;
Stubbs, K.A.; McEachern, E.J.; Davies, G.J.; et al. A potent mechanism-inspired O-GlcNAcase
inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 2008, 4, 483–490.
157. Borghgraef, P.; Menuet, C.; Theunis, C.; Louis, J.V.; Devijver, H.; Maurin, H.; Smet-Nocca, C.;
Lippens, G.; Hilaire, G.; Gijsen H.; et al. Increasing brain protein O-GlcNAc-ylation
mitigates breathing defects and mortality of Tau.P301L mice. PLoS One 2013,
158. Liu, F.; Shi, J.; Tanimukai, H.; Gu, J.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X.
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in
Alzheimer’s disease. Brain 2009, 132, 1820–1832.
159. Takahashi, M.; Tsujioka, Y.; Yamada, T.; Tsuboi, Y.; Okada, H.; Yamamoto, T.; Liposits, Z.
Glycosylation of microtubule-associated protein tau in Alzheimer’s disease brain.
Acta Neuropathol. 1999, 7, 635–641.
160. Ledesma, M.D.; Medina, M.; Avila, J.; The in vitro formation of recombinant tau polymers:
Effect of phosphorylation and glycation. Mol. Chem. Neuropathol. 1996, 27, 249–258.
161. Su, B.; Wang, X.; Lee, H.G.; Tabaton, M.; Perry, G.; Smith, M.A.; Zhu, X. Chronic oxidative
stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci. Lett. 2010,
468, 267–271.
162. Zhang, Y.J.; Xu, Y.F.; Liu, Y.H.; Yin, J.; Li, H.L.; Wang, Q.; Wang, J.Z. Peroxynitrite induces
Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.
FASEB J. 2006, 20, 1431–1442.
163. Singer, S.M.; Zainelli, G.M.; Norlund, M.A.; Lee, J.M.; Muma, N.A. Transglutaminase bonds in
neurofibrillary tangles and paired helical filament tau early in Alzheimer’s disease.
Neurochem. Int. 2002, 40, 17–30.
164. Bancher, C.; Grundke-Iqbal, I.; Iqbal, K.; Fried, V.A.; Smith, H.T.; Wisniewski, H.M.
Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of
Alzheimer disease. Brain Res. 1991, 539, 11–18.
165. Riederer, I.M.; Schiffrin, M.; Kovari, E.; Bouras, C.; Riederer, B.M. Ubiquitination and cysteine
nitrosylation during aging and Alzheimer’s disease. Brain Res. Bull. 2009, 80, 233–241.
166. Takahashi, K.; Ishida, M.; Komano, H.; Takahashi, H. SUMO-1 immunoreactivity co-localizes
with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci. Lett.
2008, 441, 90–93.
167. Newman, M.; Musgrave, I.F.; Lardelli, M. Alzheimer disease: Amyloidogenesis, the presenilins
and animal models. Biochim. Biophys. Acta 2007, 1772, 285–297.
168. Amadoro, G.; Corsetti, V.; Ciotti, M.T.; Florenzano, F.; Capsoni, S.; Amato, G.; Calissano, P.
Endogenous causes cell death via early tau phosphorylation. Neurobiol. Aging 2011, 32,
169. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems
on the road to therapeutics. Science 2002, 297, 353–356.
170. Ittner, L.M.; Götz, J. Amyloid-β and tau—A toxic pas de deux in Alzheimer’s disease.
Nat. Rev. Neurosci. 2011, 12, 67–72.
Int. J. Mol. Sci. 2014, 15 4707
171. Vossel, K.A.; Zhang, K.; Brodbeck, J.; Daub, A.C.; Sharma, P.; Finkbeiner, S.; Cui, B.;
Mucke, L. Tau reduction prevents Aβ-induced defects in axonal transport. Science 2010, 330, 198.
172. Fein, J.A.; Sokolow, S.; Miller, C.A.; Vinters, H.V.; Yang, F.; Cole, G.M.; Gylys, K.H.
Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes.
Am. J. Pathol. 2008, 172, 1683–1692.
173. Takahashi, R.H.; Capetillo-Zarate, E.; Lin, M.T.; Milner, T.A.; Gouras, G.K. Co-occurrence of
Alzheimer’s disease beta-amyloid and tau pathologies at synapses. Neurobiol. Aging 2010, 31,
174. Du, H.; Guo, L.; Yan, S.; Sosunov, A.A.; McKhann, G.M.; Yan, S.S. Early deficits in synaptic
mitochondria in an Alzheimer’s disease mouse model, Proc. Natl. Acad. Sci. USA 2010, 107,
175. Hamdane, M.; Dourlen, P.; Bretteville, A.; Sambo, A.V.; Ferreira, S.; Ando, K.; Kerdraon, O.;
Bégard, S.; Geay, L.; Lippens, G.; et al. Pin1 allows for differential Tau dephosphorylation in
neuronal cells. Mol. Cell. Neurosci. 2006, 1–2, 155–160.
176. Lim, J.; Balastik, M.; Lee, T.H.; Nakamura, K.; Liou, Y.C.; Sun, A.; Finn, G.; Pastorino, L.;
Lee, V.M.; Lu, K.P. Pin1 has opposite effects on wild-type and P301L tau stability and
tauopathy. J. Clin. Investig. 2008, 118, 1877–1889.
177. Bulbarelli, A.; Lonati, E.; Cazzaniga, E.; Gregori, M.; Masserini, M. Pin1 affects Tau
phosphorylation in response to Aβ-oligomers. Mol. Cell. Neurosci. 2009, 42, 75–80.
178. Ma, S.L.; Pastorino, L.; Zhou, X.Z.; Lu, K.P. Prolyl isomerase Pin1 promotes amyloid precursor
protein (APP) turnover by inhibiting glycogen synthase kinase-3β (GSK3β) activity: Novel
mechanism for Pin1 to protect against Alzheimer disease. J. Biol. Chem. 2012, 287, 6969–6973.
179. Tamayev, R.; Zhou, D.; D’Adamio, L. The interactome of the amyloid-β precursor protein
family members is shaped by phosphorylation of their intracellular domains. Mol. Neurodegener.
2009, 4, 28.
180. Williamson, R.; Usardi, A.; Hanger, D.P.; Anderton, B.H. Membrane-bound beta-amyloid
oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FEBS J. 2008, 22,
181. Roberson, E.D.; Halabisky, B.; Yoo, J.W.; Yao, J.; Chin, J.; Yan, F.; Wu, T.; Hamto, P.;
Devidze, N.; Yu, G.Q.; et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive
impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J. Neurosci.
2011, 31, 700–711.
182. Hernandez, P.; Lee, G.; Sjoberg, M.; Maccioni, R.B. Tau phosphorylation by cdk5 and Fyn in
response to amyloid peptide Abeta (2535): Involvement of lipid rafts. J. Alzheimers. Dis. 2009,
16, 149–156.
183. Scales, T.M.; Derkinderen, P.; Leung, K.Y.; Byers, H.L.; Ward, M.A.; Price, C.; Bird, I.N.;
Perera, T.; Kellie, S.; Williamson, R.; et al. Tyrosine phosphorylation of tau by the SRC family
kinases lck and fyn. Mol. Neurodegener. 2011, 6, 12.
184. Bhaskar, K.; Hobbs, G.A.; Yen, S.H.; Lee, G. Tyrosine phosphorylation of tau accompanies
disease progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol.
2010, 36, 462–477.
Int. J. Mol. Sci. 2014, 15 4708
185. Usardi, A.; Pooler, A.M.; Seereeram, A.; Reynolds, C.H.; Derkinderen, P.; Anderton, B.;
Hanger, D.P.; Noble, W.; Williamson, R. Tyrosine phosphorylation of tau regulates its
interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of
tau. FEBS J. 2011, 278, 2927–2937.
186. Pritchard, S.M.; Dolan, P.J.; Vitkus, A.; Johnson, G.W.V. The toxicity of tau in Alzheimer
disease: Turnover, targets and potential therapeutics. J. Cell. Mol. Med. 2011, 15, 1621–1635.
187. Dou, F.; Netzer, W.J.; Tanemura, K.; Li, F.; Hartl, F.U.; Takashima, A.; Gouras, G.K.;
Greengard, P.; Xu, H. Chaperones increase association of tau protein with microtubules.
Proc. Natl. Acad. Sci. USA 2003, 100, 721–726.
188. Miyata, Y.; Koren, J., III; Kiray, J.; Dickey, C.A.; Gestwicki, J.E. Molecular chaperones and
regulation of tau quality control:strategies for drug discovery in tauopathies. Futur. Med. Chem.
2011, 3, 1523–1537.
189. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; de Lucia, M.;
McGowan, E.; Lewis, J.; Prihar, G.; et al. CHIP and Hsp70 regulate tau ubiquitination,
degradation and aggregation. Hum. Mol. Genet. 2004, 13, 703–714.
190. Jinwal, U.K.; O’Leary, J.C., III; Borysov, S.I.; Jones, J.R.; Li, Q.; Koren, J., III; Abisambra, J.F.;
Vestal, G.D.; Lawson, L.Y.; Johnson, A.G.; et al. Hsc70 rapidly engages tau after microtubule
destabilization. J. Biol. Chem. 2010, 285, 16798–16805.
191. Jinwal, U.K.; Koren, J., III; Borysov, S.I.; Schmid, A.B.; Abisambra, J.F.; Blair, L.J.;
Johnson, A.G.; Jones, J.R.; Shults, C.L.; O’Leary, J.C., III; et al. The Hsp90 cochaperone,
FKBP51, increases tau stability and polymerizes microtubules. J. Neurosci. 2010, 30, 591–599.
192. Tortosa, E.; Santa-Maria, I.; Moreno, F.; Lim, F.; Perez, M.; Avila, J. Binding of Hsp90 to tau
promotes a conformational change and aggregation of tau protein. J. Alzheimers Dis. 2009, 17,
193. Dickey, C.A.; Dunmore, J.; Lu, B.; Wang, J.W.; Lee, W.C.; Kamal, A.; Burrows, F.;
Eckman, C.; Hutton, M.; Petrucelli, L. HSP induction mediates selective clearance of tau
phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 2006,
20, 753–765.
194. Dickey, C.A.; Koren, J.; Zhang, Y.J.; Xu, Y.F.; Jinwal, U.K.; Birnbaum, M.J.; Monks, B.;
Sun, M.; Cheng, J.Q.; Patterson, C.; et al. Akt and CHIP coregulate tau degradation through
coordinated interactions. Proc. Natl. Acad. Sci. USA 2008, 105, 3622–3627.
195. Cao, W.; Konsolaki, M. FKBP immunophilins and Alzheimer’s disease: A chaperoned affair.
J. Biosci. 2011, 36, 493–498.
196. Blair, L.J.; Nordhues, B.A.; Hill, S.E.; Scaglione, K.M.; OLeary, J.C., III; Fontaine, S.N.;
Breydo, L.; Zhang, B.; Li, P.; Wang, L.; et al. Accelerated neurodegeneration through
chaperone-mediated oligomerization of tau. J. Clin. Investig. 2013, 123, 4158–4169.
197. Chambraud, B.; Sardin, E.; Giustiniani, J.; Dounane, O.; Schumacher, M.; Goedert, M.;
Baulieu, E. A role for FKBP52 in Tau protein function. Proc. Natl. Acad. Sci. USA 2010, 107,
198. Korff, A.; Liu, C.; Ginghina, C.; Shi, M.; Zhang, J. α-Synuclein in cerebrospinal fluid of
Alzheimer’s disease and mild cognitive impairment. J. Alzheimers Dis. 2013, 36, 679–688.
Int. J. Mol. Sci. 2014, 15 4709
199. Hashiguchi, M.; Hashiguchi, T. Kinase-Kinase Interaction and Modulation of Tau
Phosphorylation. Int. Rev. Cell. Mol. Biol. 2013, 300, 121–160.
200. Kawakami, F.; Suzuki, M.; Shimada, N.; Kagiya, G.; Ohta, E.; Tamura, K.; Maruyama, H.;
Ichikawa, T. Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β. FEBS J.
2011, 278, 4895–4904.
201. Qureshi, H.Y.; Paudel, H.K. Parkinsonian neurotoxin 1-methyl-4phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and α-synuclein mutations promote Tau protein phosphorylation at
and destabilize microtubule cytoskeleton in vitro. J. Biol. Chem. 2011, 286, 5055–5068.
202. Whiteman, I.T.; Gervasio, O.L.; Cullen, K.M.; Guillemin, G.J.; Jeong, E.V.; Witting, P.K.;
Antao, S.T.; Minamide, L.S.; Bamburg, J.R.; Goldsbury, C. Activated ADF/cofilin sequesters
phosphorylated microtubuleassociated-protein during the assembly of Alzheimer-like neuritic
cytoskeletal striations. J. Neurosci. 2009, 29, 12994.
203. Poulain, F.E.; Sobel, A. The microtubule network and neuronal morphogenesis: Dynamic and
coordinated orchestration through multiple players. Mol. Cell. Neurosci. 2010, 43, 15–32.
204. Grimm-Günter, E.S.; Milbrandt, M.; Merkl, B.; Paulsson, M.; Plomann, M. PACSIN proteins
bind tubulin andpromotemicrotubule assembly. Exp. Cell Res. 2008, 314, 1991–2003.
205. Liu, Y.; Lv, K.; Li, Z.; Yu, A.C.H.; Chen, J.; Teng, J. PACSIN1, a Tau-interacting protein,
regulates axonal elongation and branching by facilitating microtubule instability. J. Biol. Chem.
2012, 287, 39911–39924.
206. Crowther, R.A.; Goedert, M. Abnormal tau-containing filaments in neurodegenerative diseases.
J. Struct. Biol. 2000, 130, 271–279.
207. Kosik, K.S.; Shimura, H. Phosphorylated tau and the neurodegenerative foldopathies.
Biochim. Biophys. Acta 2005, 1739, 298–310.
208. Avila, J.; Lucas, J.J.; Perez, M.; Hernandez, F. Role of Tau in both physiological and
pathological conditions. Physiol. Rev. 2004, 84, 361–384.
209. Jeganathan, S.; Hascher, A.; Chinnathambi, S.; Biernat, J.; Mandelkow, E.M.; Mandelkow, E.
Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the
paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 2008,
283, 32066–32076.
210. Hyman, B.T.; Augustinack, J.C.; Ingelsson, M. Transcriptional and conformational changes of
the tau molecule in Alzheimer’s disease. Biochim. Biophys. Acta 2005, 1739, 150–157.
211. Delacourte, A.; Buee, L. Normal and pathological Tau proteins as factors for microtubule
assembly. Int. Rev. Cytol. 1997, 171, 167–224.
212. Johnson, G.V.; Stoothoff, W.H. Tau phosphorylation in neuronal cell function and dysfunction.
J. Cell Sci. 2004, 117, 5721–5729.
213. Drechsel, D.N.; Hyman, A.A.; Cobb, M.H.; Kirschner, M.W. Modulation of the dynamic
instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3,
214. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.; Gertz, H.N.; Xuereb, J.H.; Paykel, E.S.; Brayne, C.;
Huppert, F.A.; Mukaetova-Ladinska, E.B.; Mena, R.; et al. Quantitative analysis of tau protein in
paired helical filament preparations: Implications for the role of tau protein phosphorylation in
PHF assembly in Alzheimer’s disease. Neurobiol. Aging 1995, 16, 409–417.
Int. J. Mol. Sci. 2014, 15 4710
215. Feuillette, S.; Miguel, L.; Frébourg, T.; Campion, D.; Lecourtois, M. Drosophila models of
human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic
phosphorylated forms of the protein. J. Neurochem. 2010, 113, 895–903.
216. Rocher, A.B.; Crimins, J.L.; Amatrudo, J.M.; Kinson, M.S.; Todd-Brown, M.A.; Lewis, J.;
Luebke, J.I. Structural and functional changes in tau mutant mice neurons are not linked to the
presence of NFTs. Exp. Neurol. 2010, 223, 385–393.
217. Cowan, C.M.; Bossing, T.; Page, A.; Shepherd, D.; Mudher, A. Soluble hyper-phosphorylated
tau causes microtubule breakdown and functionally compromises normal tau in vivo.
Acta Neuropathol. 2010, 120, 593–604.
218. Cowan, C.M.; Mudher, A. Are tau aggregates toxic or protective in tauopathies? Front. Neurol.
2013, 13, 4–114.
219. Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M. Evidence that non-fibrillar tau causes pathology
linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 2008, 14, 393–9.
220. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease.
Hum. Vaccin. 2010, 6, 931–5.
221. Spires-Jones, T.L.; Kopeikina, K.J.; Koffie, R.M.; de Calignon, A.; Hyman, B.T. Are tangles as
toxic as they look? J. Mol. Neurosci. 2011, 45, 438–44.
222. Patterson, K.R.; Ward, S.M.; Combs, B.; Voss, K.; Kanaan, N.M.; Morfini, G.; Brady, S.T.;
Gamblin, T.C.; Binder, L.I. Heat shock protein 70 prevents both tau aggregation and the
inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 2011, 50,
223. Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Sengupta, U.; Clos, A.L.; Jackson, G.R.;
Kayed, R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in
wild-typemice. Mol. Neurodegener. 2011, 6, 39.
224. Berger, Z.; Roder, H.; Hanna, A.; Carlson, A.; Rangachari, V.; Yue, M.; Wszolek, Z.; Ashe, K.;
Knight, J.; Dickson, D.; et al. Accumulation of pathological tau species and memory loss in a
conditional model of tauopathy. J. Neurosci. 2007, 27, 3650–3662.
225. Sahara, N.; Maeda, S.; Murayama, M.; Suzuki, T.; Dohmae, N.; Yen, S.H.; Takashima, A.
Assembly of two distinct dimers and higher-orderoligomers from full-length tau.
Eur. J. Neurosci. 2007, 25, 3020–3029.
226. Spires-Jones, T.L.; Stoothoff, W.H.; de Calignon, A.; Jones, P.B.; Hyman B.T. Tau
pathophysiology in neurodegeneration: A tangled issue. Trends Neurosci. 2009, 32, 150–159.
227. Haase, C.; Stieler, J.T.; Arendt, T.; Holzer, M. Pseudophosphorylation of tau protein alters its
ability for self-aggregation. J. Neurochem. 2004, 88, 1509–1520.
228. Cho, J.H.; Johnson, G.V. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase
3beta (GSK3beta) plays a critical role in regulating tau’s ability to bind and stabilize
microtubules. J. Neurochem. 2004, 88, 349–358.
229. Sun, Q.; Gamblin, T.C. Pseudohyperphosphorylation causing AD-like changes in tau has
significant effects on its polymerization. Biochemistry 2009, 48, 6002–6011.
230. Min, S.W.; Cho, S.H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.;
Shen, Y.; Masliah, E.; Mukherjee, C.; et al. Acetylation of tau inhibits its degradation and
contributes to tauopathy. Neuron 2010, 67, 953–966.
Int. J. Mol. Sci. 2014, 15 4711
231. Irwin, D.J.; Cohen, T.J.; Grossman, M.; Arnold, S.E.; Xie, S.X.; Lee, V.M.; Trojanowski, J.Q.
Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies.
Brain 2012, 135, 807–818.
232. Alonso, A.D.; Grundke-Iqbal, I.; Barra, H.S.; Iqbal, K. Abnormal phosphorylation of tau and the
mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated
proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad.
Sci. USA 1997, 94, 298–303.
233. Alonso, A.D.; Zaidi, T.; Novak, M.; Grundke-Iqbal, I.; Iqbal, K. Hyperphosphorylation induces
self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad.
Sci. USA 2001, 98, 6923–6928.
234. Duan, A.R.; Goodson, H.V. Taxol-stabilized microtubules promote the formation of filaments
from unmodified full-length Tau in vitro. Mol. Biol. Cell 2012, 23, 4796–4806,
235. Masliah, E.; Iimoto, D.S.; Saitoh, T.; Hansen, L.A.; Terry, R.D. Increased immunoreactivity of
brain spectrin in Alzheimer disease: A marker for synapse loss? Brain Res. 1990, 531, 36–44.
236. Nelson, P.T.; Alafuzoff, I.; Bigio, E.H.; Bouras, C.; Braak, H.; Cairns, N.J.; Castellani, R.J.;
Crain, B.J.; Davies, P.; del Tredici, K.; et al. Correlation of Alzheimer disease neuropathologic
changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71,
237. Billingsley, M.L.; Kincaid, R.L. Regulated phosphorylation and dephosphorylation of tau
protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration.
Biochem. J. 1997, 323, 577–591.
238. Bunker, J.M.; Kamath, K.; Wilson, L.; Jordan, M.A.; Feinstein, S.C. FTDP-17 mutations
compromise the ability of tau to regulate microtubule dynamics in cells. J. Biol. Chem. 2006,
281, 11856–11863.
239. Díaz-Nido, J.; Wandosell, F.; Avila, J. Glycosaminoglycans and beta-amyloid, prion and tau
peptides in neurodegenerative diseases. Peptides 2002, 23, 1323–1332.
240. Stokin, G.B.; Goldstein, L.S. Axonal transport and Alzheimer’s disease. Annu. Rev. Biochem.
2006, 75, 607–627.
241. Kanaan, N.M.; Pigino, G.F.; Brady, S.T.; Lazarov, O.; Binder, L.I.; Morfini, G.A.
Axonal degeneration in Alzheimer’s disease: When signaling abnormalities meet the axonal
transport system. Exp. Neurol. 2013, 246, 44–53.
242. Chevalier-Larsen, E.; Holzbaur, E.L. Axonal transport and neurodegenerative disease.
Biochim. Biophys. Acta 2006, 1762, 1094–1108.
243. Lau, C.G.; Zukin, R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric
disorders. Nat. Rev. Neurosci. 2007, 8, 413–426.
244. Van Spronsen, M.; Hoogenraad, C.C. Synapse pathology in psychiatric and neurologic disease.
Curr. Neurol. Neurosci. Rep. 2010, 10, 207–214.
245. Kapitein, L.C.; Hoogenraad, C.C. Which way to go? Cytoskeletal organization and polarized
transport in neurons. Mol. Cell. Neurosci. 2011, 46, 9–20.
246. Hirokawa, N.; Noda, Y. Intracellular transport and kinesin superfamily proteins, KIFs: Structure,
function, and dynamics. Physiol. Rev. 2008, 88, 1089–1118.
Int. J. Mol. Sci. 2014, 15 4712
247. Falzone, T.L.; Gunawardena, S.; McCleary, D.; Reis, G.F.; Goldstein, L.S. Kinesin-1 transport
reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in
animal models of tauopathies. Hum. Mol. Genet. 2010, 19, 4399–4408.
248. Terada, S.; Kinjo, M.; Aihara, M.; Takei, Y.; Hirokawa, N. Kinesin-1/Hsc70-dependent
mechanism of slow axonal transport and its relation to fast axonal transport. EMBO J. 2010, 29,
249. Gunawardena, S.; Goldstein, L.S. Cargo-carrying motor vehicles on the neuronal highway:
Transport pathways and neurodegenerative disease. J. Neurobiol. 2004, 58, 258–271.
250. Perlson, E.; Maday, S.; Fu, M.M.; Moughamian, A.J.; Holzbaur, E.L. Retrograde axonal
transport: Pathways to cell death? Trends Neurosci. 2010, 33, 335–344.
251. Bendiske, J.; Caba, E.; Brown, Q.B.; Bahr, B.A. Intracellular deposition, microtubule
destabilization, and transport failure: An earlypathogenic cascade leading to synaptic decline.
J. Neuropathol. Exp. Neurol. 2002, 61, 640–650.
252. Kamal, A.; Stokin, G.B.; Yang, Z.; Xia, C.H.; Goldstein, L.S. Axonal transport of amyloid
precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I.
Neuron 2000, 28, 449–459.
253. Morel, M.; Héraud, C.; Nicaise, C.; Suain, V.; Brion, J.P. Levels of kinesin light chain and
dynein intermediate chain are reduced in the frontal cortex in Alzheimer’s disease: Implications
for axoplasmic transport. Acta Neuropathol. 2012, 123, 71–84.
254. Hashimoto, Y.; Tsuji, O.; Niikura, T.; Yamagishi, Y.; Ishizaka, M.; Kawasumi, M.; Chiba, T.;
Kanekura, K.; Yamada, M.; Tsukamoto, E.; et al. Involvement of c-Jun N-terminal kinase in
amyloid precursor protein-mediated neuronal cell death. J. Neurochem. 2003, 84, 864–877.
255. Futerman, A.H.; Banker, G.A. The economics of neurite outgrowth—The addition of new
membrane to growing axons. Trends Neurosci. 1996, 19, 144–149.
256. Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E.; Mandelkow, E.M. Tau blocks traffic of
organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress.
J. Cell Biol. 2002, 18, 1051–1063.
257. Mandelkow, E.M.; Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E. Clogging of axons by tau,
inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 2003, 24, 1079–1085.
258. Calissano, P.; Matrone, C.; Amadoro, G. Nerve growth factor as a paradigm of neurotrophins
related to Alzheimer’s disease. Dev. Neurobiol. 2010, 70, 372–383.
259. Thies, E.; Mandelkow, E.M. Missorting of tau in neurons causes degeneration of synapses that
can be rescued by the kinase MARK2/Par-1. J. Neurosci. 2007 27, 2896–2907.
260. Tatebayashi, Y.; Haque, N.; Tung, Y.C.; Iqbal, K.; Grundke-Iqbal, I. Role of tau phosphorylation
by glycogen synthase kinase-3beta in the regulation of organelle transport. J. Cell Sci. 2004,
117, 1653–1663.
261. Watson, F.L.; Heerssen, H.M.; Moheban, D.B.; Lin, M.Z.; Sauvageot, C.M.; Bhattacharyya, A.;
Pomeroy, S.L.; Segal, R.A. Rapid nuclear responses to target-derived neurotrophins require
retrograde transport of ligand-receptor complex. J. Neurosci. 1999, 15, 7889–7900.
262. Sandow, S.L.; Heydon, K.; Weible, M.W., II; Reynolds, A.J.; Bartlett, S.E.; Hendry, I.A.
Signaling organelle for retrograde axonal transport of internalized neurotrophins from the nerve
terminal. Immunol. Cell Biol. 2000, 78, 430–435.
Int. J. Mol. Sci. 2014, 15 4713
263. Bhattacharyya, A.; Watson, F.L.; Pomeroy, S.L.; Zhang, Y.Z.; Stiles, C.D.; Segal, R.A.
High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk
receptors. J. Neurobiol. 2002, 51, 302–312.
264. Heerssen, H.M.; Pazyra, M.F.; Segal, R.A. Dynein motors transport activated Trks to promote
survival of target-dependent neurons. Nat. Neurosci. 2004, 7, 596–604.
265. Yano, H.; Lee, F.S.; Kong, H.; Chuang, J.; Arevalo, J.; Perez, P.; Sung, C.; Chao, M.V.
Association of Trk neurotrophin receptors with components of the cytoplasmic dynein motor.
J. Neurosci. 2001, 21, RC125.
266. Yano, H.; Chao, M.V. Mechanisms of neurotrophin receptor vesicular transport. J. Neurobiol.
2004, 58, 244–257.
267. Riccio, A.; Pierchal, B.A.; Ciarallo, C.L.; Ginty, D.D. A NGF-TrkA-mediated retrograde signal
to transcription factor CREB in sympathetic neurons. Science 1997, 277, 1097–1100.
268. Yano, H.; Chao, M.V. Biochemical characterization of intracellular membranes bearing Trk
neurotrophin receptors. Neurochem. Res. 2005, 30, 767–777.
269. Wu, C.; Ramirez, A.; Cui, B.; Ding, J.; Delcroix, J.D.; Valletta, J.S.; Liu, J.J.; Yang, Y.; Chu, S.;
Mobley, W.C. A functional dynein-microtubule network is required for NGF signaling through
the Rap1/MAPK pathway. Traffic 2007, 8, 1503–1520.
270. Salehi, A.; Delcroix, J.D.; Swaab, D.F. Alzheimer’s disease and NGF signaling.
J. Neural Transm. 2004, 111, 323–345.
271. Schindowski, K.; Belarbi, K.; Buée, L. Neurotrophic factors in Alzheimer’s disease: Role of
axonal transport. Genes Brain Behav. 2008, 1, 43–56.
272. Lazarov, O.; Morfini, G.A.; Pigino, G.; Gadadhar, A.; Chen, X.; Robinson, J.; Ho, H.;
Brady, S.T.; Sisodia, S.S. Impairments in fast axonal transport and motor neuron deficits in
transgenic mice expressing familial Alzheimer’s disease-linked mutant presenilin 1. J. Neurosci.
2007, 27, 7011–7020.
273. Corsetti, V.; Amadoro, G.; Gentile, A.; Capsoni, S.; Ciotti, M.T.; Cencioni, M.T.; Atlante, A.;
Canu, N.; Rohn, T.T.; Cattaneo, A.; et al. Identification of a caspase-derived N-terminal tau fragment
in cellular and animal Alzheimer’s disease models. Mol. Cell. Neurosci. 2008, 38, 381–392.
274. Magnani, E.; Fan, J.; Gasparini, L.; Golding, M.; Williams, M.; Schiavo, G.; Goedert, M.;
Amos, L.A.; Spillantini, M.G. Interaction of tau protein with the dynactin complex. EMBO J.
2007, 31, 4546–4554.
275. Matrone, C.; Ciotti, M.T.; Mercanti, D.; Marolda, R.; Calissano, P. NGF and BDNF signaling
control amyloidogenic route and Ab production in hippocampal neurons. Proc. Natl. Acad. Sci. USA
2008, 105, 13139–13144.
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
... Although highly enriched p-tau in the brain can be transported to the peripheral system, only a small fraction of p-tau enters the blood, making it difficult to measure the low levels of various p-tau proteins in the blood (Dugger and Whiteside, 2016;Lakshmi and Essa, 2020;Sun and Zhou, 2022). It has been demonstrated that there are approximately 85 phosphorylation sites on the tau protein, which can result in different p-tau isoforms in blood samples, posing a great challenge for accurate and specific p-tau detection (Martin and Latypova, 2011;Mietelska--Porowska and Wasik, 2014). Enzyme-linked immunosorbent assay (ELISA) is the most widely used immunoassay for biomarker detection. ...
... However, SERS-based sensors mainly rely on the intrinsic Raman vibrational information of phosphorylated tyrosine, serine, threonine, or histidine residues (Ma and Liu, 2021;Park and Cho, 2020). Besides, p-tau has approximately 85 putative phosphorylation sites on tyrosine, serine, threonine, or histidine residues, such as p-tau 181 , p-tau 217 , and p-tau 396 , making SERS-based assays lack specificity (Aragão Gomes and Uytterhoeven, 2021;Liu and Li, 2007;Martin and Latypova, 2011;Mietelska-Porowska and Wasik, 2014). Inspired by pioneer research and our previous work (Hu and Yang, 2022;Zhang and Du, 2021a), we propose a colorimetric and SERS dual-mode magnetic immunosensor for the ultrasensitive detection of blood p-tau in AD. ...
Phosphorylation of tau at Ser 396, 404 (p-tau396,404) is the earliest phosphorylation event and a promising biomarker for the early diagnosis of Alzheimer's disease (AD). However, the detection of blood p-tau is challenging because of its low abundance, easy degradation, and complex formation with various blood proteins or cells, often leading to the underestimation of p-tau levels in conventional plasma-based assays. Herein, we developed a colorimetric and surface-enhanced Raman scattering (SERS) dual-mode magnetic immunosensor for highly sensitive, specific, and robust detection of p-tau396,404 in whole blood samples. The detection assay was based on an immunoreaction between p-tau396,404 proteins, wherein antibody-modified superparamagnetic iron oxide nanoparticles act as recognition elements to capture p-tau396,404 in blood, and then horseradish peroxidase- and Raman tags label the corresponding paired antibody as a reporter to provide high signal-to-noise ratios for the immunosensor. This dual-mode immunosensor achieved identified as low as 1.5 pg/mL of p-tau396,404 in the blood in SERS mode and 24 pg/mL in colorimetric mode by the naked eye. More importantly, this immunosensor rapidly and accurately distinguished AD patients from healthy individuals based on blood p-tau396,404 levels, and also had the potential to distinguish AD patients of different severities. Therefore, the dual-mode immunosensor is promising for rapid clinical diagnosis of AD, especially in large-scale AD screening.
... (51) Its gene is located on chromosome 17q21.31 and has six isoforms produced by alternative splicing, (52) with three major domains that differ in number of amino acids. (53) Under physiological conditions, the tau protein exists in the phosphorylated form in the axon. ...
... Among the main enzymes involved in this process are protein kinase A (PKA), c-Jun amino-terminal kinase (JNK), tau protein kinase I (TPKI), GSK3, dualspecificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), and AMP-activated protein kinase (AMPK). (52) The presence of inflammatory mediators, such as TNF-alpha, F-KB), and interleukins, contributes to the activity of the mitogen-activated protein kinase (MAPK) and CDK-5). In vitro studies have shown that casein kinase can also phosphorylate tau protein. ...
Full-text available
Abstract Alzheimer’s disease is a neurodegenerative condition that causes changes in memory and cognition, in addition to behavioral disorders, and most commonly affects the elderly. Several studies in the literature have presented therapeutic measures in an attempt to interfere with the pathogenic mechanisms of the disease and to mitigate its clinical manifestations. Some factors, such as excitotoxicity, cholinergic dysfunctions, oxidative stress, tau protein hyperphosphorylation, changes in amyloid-beta peptide metabolism, herpes viruses, apolipoprotein E, glycogen synthase kinase 3, insulin resistance, and the endocannabinoid system seem to be related to pathophysiology of Alzheimer’s disease. Given this, a literature review was carried out to address the molecular mechanisms associated with the pathophysiological hypotheses previously mentioned, aiming to better understanding their underlying causes and contributing to possible pharmacological strategies about treatment of the disease.
... L'étude de la composition des agrégats cérébraux des protéinopathies primaires a permis de mettre en évidence une hyperphosphorylation de la protéine Tau pathologique (241). Ce changement dans son métabolisme, associé à d'autres MPT, telles que la glycosylation ou l'acétylation, auraient pour conséquence une diminution de l'affinité de la protéine Tau pour les MTU, impliquant une déstabilisation de ces structures et in fine la perte de leur fonction de soutien et de transport (242). Les MPT anormales subies par la protéine pourraient également favoriser la formation d'agrégats de protéine Tau, notamment par une baisse de sa solubilité. ...
Les dégénérescence lobaire frontotemporale (DLFT), qui représentent la deuxième cause de troubles neurocognitifs dégénératifs chez l’adulte de moins de 65 ans, sont hétérogènes d’un point de vue clinique et peuvent présenter des recouvrements symptomatologiques avec d’autres maladies neurodégénératives mais aussi avec des pathologies psychiatriques primaires. Elles se caractérisent par la présence d’agrégats protéiques cérébraux composés principalement de protéine Tau ou de TDP-43, ainsi que par une forte proportion de cas d’origine génétique. Aucun biomarqueur protéique étiologique n’est aujourd’hui disponible pour ces maladies. Malgré une littérature riche sur le potentiel intérêt de la TDP-43 dans les fluides biologiques, les résultats des études restent aujourd’hui contrastés. Dans ce contexte, le but de ce travail de thèse était de développer des anticorps dirigés contre la TDP 43 afin de disposer d’outils potentiellement plus performants pour mettre en évidence un profil qualitatif spécifique des formes pathologiques de la protéine. Dans un premier temps, de nouveaux anticorps anti TDP 43 ont été synthétisés, dirigés contre la forme totale de la protéine ou contre une de ses formes phosphorylées. Ils ont alors été caractérisés sur des échantillons cérébraux. les profils protéiques obtenus par Western Blot en utilisant ces nouveaux anticorps se sont révélés intéressants. Leur évaluation a alors été poursuivie dans d’autres milieux biologiques. Pour cela, une méthode spécifique a notamment été développée, faisant appel à une technologie automatisée et miniaturisée dérivant du Western Blot. Dans le liquide cérébrospinal (LCS) et le plasma, aucune différence n’a pu être observée entre les patients et les contrôles. Les profils protéiques des culots plaquettaires des patients ont en revanche présentés des similitudes avec le tissu cérébral et avec des lysats de cellules humaines de culture secrétant naturellement la TDP-43. Enfin, une analyse quantitative de marqueurs non spécifiques des DLFT a été réalisée par technique SiMoA. Cette technologie ultrasensible a permis de mesurer ces protéines dans des échantillons couplés de LCS et de plasma. L’analyse des neurofilaments à chaine légère a confirmé leur intérêt comme marqueur indirect de diagnostic différentiel entre les maladies psychiatriques et les DFLT. De façon intéressante, l’hydrolase Ubiquitin carboxyl terminal L1 s’est également révélée être un bon candidat dans le LCS comme dans le plasma.
Alzheimer’s disease (AD), the foremost variant of dementia, has been associated with a menagerie of risk factors, many of which are considered to be modifiable. Among these modifiable risk factors is circadian rhythm, the chronobiological system that regulates sleep‐wake cycles, food consumption timing, hydration timing, and immune responses amongst many other necessary physiological processes. Circadian rhythm at the level of the suprachiasmatic nucleus (SCN), is tightly regulated in the human body by a host of biomolecular substances, principally the hormones melatonin, cortisol, and serotonin. In addition, photic information projected along afferent pathways to the SCN and peripheral oscillators regulates the synthesis of these hormones and mediates the manner in which they act on the SCN and its substructures. Dysregulation of this cycle, whether induced by environmental changes involving irregular exposure to light, or through endogenous pathology, will have a negative impact on immune system optimization and will heighten the deposition of Aβ and the hyperphosphorylation of the tau protein. Given these correlations, it appears that there is a physiologic association between circadian rhythm dysregulation and AD. This review will explore the physiology of circadian dysregulation in the AD brain, and will propose a basic model for its role in AD‐typical pathology, derived from the literature compiled and referenced throughout.
Full-text available
Autism spectrum disorders (ASD) are neurodevelopmental diseases characterised by deficits in social communication, restricted interests, and repetitive behaviours. The growing body of evidence points to a role for cerebellar changes in ASD pathology. Some of the findings suggest that not only motor problems but also social deficits, repetitive behaviours, and mental inflexibility associated with ASD are connected with damage to the cerebellum. However, the understanding of this brain structure’s functions in ASD pathology needs future investigations. Therefore, in this study, we generated a rodent model of ASD through a single prenatal administration of valproic acid (VPA) into pregnant rats, followed by cerebellar morphological studies of the offspring, focusing on the alterations of key cytoskeletal elements. The expression (Western blot) of α/β-tubulin and the major neuronal MT-associated proteins (MAP) such as MAP-Tau and MAP1B, MAP2, MAP6 (STOP) along with actin-crosslinking αII-spectrin and neurofilament light polypeptide (NF-L) was investigated. We found that maternal exposure to VPA induces a significant decrease in the protein levels of α/β-tubulin, MAP-Tau, MAP1B, MAP2, and αII-spectrin. Moreover, excessive MAP-Tau phosphorylation at (Ser396) along with key Tau-kinases activation was indicated. Immunohistochemical staining showed chromatolysis in the cerebellum of autistic-like rats and loss of Purkinje cells shedding light on one of the possible molecular mechanisms underpinning neuroplasticity alterations in the ASD brain.
La protéine Tau, pour Tubulin Associated Unit, est majoritairement exprimée au sein de la population neuronale. Elle appartient à la famille des protéines associées aux microtubules. Sa fonction majoritaire est de permettre la régulation de la dynamique microtubulaire afin d’assurer la modulation de nombreux mécanismes neuronaux tels que le transport axonal ou les connexions synaptiques. D’autres fonctions de Tau ont vu le jour depuis ces dernières années notamment au niveau de la signalisation cellulaire et la protection de l’ADN. A côté de ces fonctions physiologiques, la protéine Tau joue un rôle central dans un groupe de pathologies neurodégénératives regroupées sous le terme de Tauopathies. Dans ces pathologies, Tau est retrouvée sous forme agrégée et anormalement modifiée dans les neurones en dégénérescence. Dans la maladie d’Alzheimer, Tauopathie la plus fréquente, l’agrégation de Tau conduit à l’apparition d’une lésion histopathologique dénommée dégénérescence neurofibrillaire (DNF). Cette lésion montre une évolution spatiotemporelle qui est corrélée aux signes cliniques.Aujourd’hui, tous les mécanismes conduisant à l’agrégation de Tau et à la formation de la DNF ne sont pas clairement expliqués mais il apparaît clairement qu’une dérégulation des modifications post-traductionnelles est un élément conduisant à la pathologie Tau. En effet, de nombreux travaux ont montré la présence de formes tronquées dans la partie amino- et carboxy-terminale de Tau au sein de tissu cérébral provenant de patients Alzheimer. A ce jour, l’identité et le rôle de toutes les formes tronquées de Tau ne sont pas connus. C’est dans ce contexte que s’inscrit ce projet de thèse, il se concentre sur l’étude d’une nouvelle forme tronquée de Tau débutant à la Methionine11 (forme tronquée Met11-Tau). Cette forme tronquée a également été détectée avec une modification post-traductionnelle encore jamais décrite pour Tau, la N-α-acétylation (forme tronquée AcMet11-Tau).Afin d’étudier la forme tronquée AcMet11-Tau, le développement d’un anticorps monoclonal dirigé spécifiquement contre cette espèce de Tau a été réalisé au cours de ce travail de thèse. Cet outil immunologique obtenu a permis de montrer que la forme tronquée AcMet11-Tau est retrouvée précocement au sein du tissu cérébral d’un modèle de souris transgénique (Thy-Tau22) et au sein du tissu cérébral provenant de patients Alzheimer. Ainsi, ces résultats suggèrent fortement que la forme tronquée AcMet11-Tau est une espèce pathologique de Tau. En plus de ces études sur tissu cérébral, un modèle cellulaire de neuroblastome humain stable et inductible pour la protéine Tau entière et la forme tronquée Met11-Tau a été généré, en vue de déterminer le rôle de la N-α-acétylation sur Tau. Les études préliminaires ont montré que l’AcMet11-Tau ne présentait pas la même demi-vie que la protéine Tau entière. De plus, des outils de modulation du niveau de N-α-acétylation ont été validés.Ainsi, sur la base de ces résultats originaux et très prometteurs quant à l’association de la protéine AcMet11-Tau à la pathologie Tau et des outils générés, ce travail ouvre des perspectives pour réaliser des études in vivo, en vue de préciser le rôle de AcMet11-Tau dans le processus physiopathologique de la maladie d’Alzheimer. De plus, des études complémentaires sur le mécanisme de génération de cette espèce de Tau permettrait de mieux comprendre et contrecarrer la synthèse de celle-ci.
Alzheimer's disease (AD) is characterized by the presence of two types of protein deposits in the brain, amyloid plaques and neurofibrillary tangles. The first one are dense deposits of beta amyloid protein, the second one are dense deposits of the protein tau. These proteins are present in all of our brains, but in AD they act unusually, leading to neuronal degeneration. This review will provide an overview of the AD, including the role of amyloid beta and tau, and mechanisms that lead to the formation of plaques and tangles. The review will also cover the existing researches that have focused on the inhibition of amyloid beta formation, cholinesterase, tau hyperphosphorylation, the pathogenic mechanisms of apoE4, and GSK-3 as a solution that could be used to slow or prevent the disease.
Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood‐based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.
Full-text available
Hyperphosphorylated forms of the neuronal microtubule (MT)-associated protein tau are major components of Alzheimer’s disease paired helical filaments. Previously, we reported that ABαC, the dominant brain isoform of protein phosphatase 2A (PP2A), is localized on MTs, binds directly to tau, and is a major tau phosphatase in cells. We now describe direct interactions among tau, PP2A, and MTs at the submolecular level. Using tau deletion mutants, we found that ABαC binds a domain on tau that is indistinguishable from its MT-binding domain. ABαC binds directly to MTs through a site that encompasses its catalytic subunit and is distinct from its binding site for tau, and ABαC and tau bind to different domains on MTs. Specific PP2A isoforms bind to MTs with distinct affinities in vitro, and these interactions differentially inhibit the ability of PP2A to dephosphorylate various substrates, including tau and tubulin. Finally, tubulin assembly decreases PP2A activity in vitro, suggesting that PP2A activity can be modulated by MT dynamics in vivo. Taken together, these findings indicate how structural interactions among ABαC, tau, and MTs might control the phosphorylation state of tau. Disruption of these normal interactions could contribute significantly to development of tauopathies such as Alzheimer’s disease.
Full-text available
The microtubule associated protein tau causes primary and secondary tauopathies by unknown molecular mechanisms. Post-translational O-GlcNAc-ylation of brain proteins was demonstrated here to be beneficial for Tau.P301L mice by pharmacological inhibition of O-GlcNAc-ase. Chronic treatment of ageing Tau.P301L mice mitigated their loss in body-weight and improved their motor deficits, while the survival was 3-fold higher at the pre-fixed study endpoint at age 9.5 months. Moreover, O-GlcNAc-ase inhibition significantly improved the breathing parameters of Tau.P301L mice, which underpinned pharmacologically the close correlation of mortality and upper-airway defects. O-GlcNAc-ylation of brain proteins increased rapidly and stably by systemic inhibition of O-GlcNAc-ase. Conversely, biochemical evidence for protein Tau.P301L to become O-GlcNAc-ylated was not obtained, nor was its phosphorylation consistently or markedly affected. We conclude that increasing O-GlcNAc-ylation of brain proteins improved the clinical condition and prolonged the survival of ageing Tau.P301L mice, but not by direct biochemical action on protein tau. The pharmacological effect is proposed to be located downstream in the pathological cascade initiated by protein Tau.P301L, opening novel venues for our understanding, and eventually treating the neurodegeneration mediated by protein tau.
Full-text available
Mislocalization and aggregation of Aβ and Tau combined with loss of synapses and microtubules (MTs) are hallmarks of Alzheimer disease. We exposed mature primary neurons to Aβ oligomers and analysed changes in the Tau/MT system. MT breakdown occurs in dendrites invaded by Tau (Tau missorting) and is mediated by spastin, an MT-severing enzyme. Spastin is recruited by MT polyglutamylation, induced by Tau missorting triggered translocalization of TTLL6 (Tubulin-Tyrosine-Ligase-Like-6) into dendrites. Consequences are spine loss and mitochondria and neurofilament mislocalization. Missorted Tau is not axonally derived, as shown by axonal retention of photoconvertible Dendra2-Tau, but newly synthesized. Recovery from Aβ insult occurs after Aβ oligomers lose their toxicity and requires the kinase MARK (Microtubule-Affinity-Regulating-Kinase). In neurons derived from Tau-knockout mice, MTs and synapses are resistant to Aβ toxicity because TTLL6 mislocalization and MT polyglutamylation are prevented; hence no spastin recruitment and no MT breakdown occur, enabling faster recovery. Reintroduction of Tau re-establishes Aβ-induced toxicity in TauKO neurons, which requires phosphorylation of Tau's KXGS motifs. Transgenic mice overexpressing Tau show TTLL6 translocalization into dendrites and decreased MT stability. The results provide a rationale for MT stabilization as a therapeutic approach.
Using a novel PCR approach, we have cloned a cDNA encoding the entire high molecular weight tau molecule from rat dorsal root ganglia. The resulting 2080 bp cDNA differs from low molecular weight rat brain tau by the insertion of a novel 762 bp region (exon 4a) between exons 4 and 5. This cDNA clone is identical in sequence with a high molecular weight tau (HMW) cDNA from rat PC12 tumor cells and is closely related to a HMW tau cDNA from mouse N115 tumor cells. In vitro transcription/translation produces a protein that migrates on SDS-PAGE with the same apparent molecular weight as HMW tau purified from rat sciatic nerve. The HMW tau protein is generated from an 8 kb mRNA, which can be detected by northern blots in peripheral ganglia, but not in brain. A more sensitive assay using PCR and Southern blot analysis demonstrates the presence of exon 4a in spinal cord and in retina. In combination with immunohistochemical studies of spinal cord, these data suggest that HMW tau, though primarily in the peripheral nervous system, is also expressed in limited areas of the central nervous system, although its presence cannot be detected in the cerebral cortices.
A monoclonal antibody to the microtubule-associated protein tau (tau) labeled some neurofibrillary tangles and plaque neurites, the two major locations of paired-helical filaments (PHF), in Alzheimer disease brain. The antibody also labeled isolated PHF that had been repeatedly washed with NaDodSO4. Dephosphorylation of the tissue sections with alkaline phosphatase prior to immunolabeling dramatically increased the number of tangles and plaques recognized by the antibody. The plaque core amyloid was not stained in either dephosphorylated or nondephosphorylated tissue sections. On immunoblots PHF polypeptides were labeled readily only when dephosphorylated. In contrast, a commercially available monoclonal antibody to a phosphorylated epitope of neurofilaments that labeled the tangles and the plaque neurites in tissue did not label any PHF polypeptides on immunoblots. The PHF polypeptides, labeled with the monoclonal antibody to tau, electrophoresed with those polypeptides recognized by antibodies to isolated PHF. The antibody to tau-labeled microtubules from normal human brains assembled in vitro but identically treated Alzheimer brain preparations had to be dephosphorylated to be completely recognized by this antibody. These findings suggest that tau in Alzheimer brain is an abnormally phosphorylated protein component of PHF.
Loss of synapses and dying back of axons are considered early events in brain degeneration during Alzheimer’s disease. This is accompanied by an aberrant behavior of the microtubule-associated protein tau (hyperphosphorylation, aggregation). Since microtubules are the tracks for axonal transport, we are testing the hypothesis that tau plays a role in the malfunctioning of transport. Experiments with various neuronal and non-neuronal cells show that tau is capable of reducing net anterograde transport of vesicles and cell organelles by blocking the microtubule tracks. Thus, a misregulation of tau could cause the starvation of synapses and enhanced oxidative stress, long before tau detaches from microtubules and aggregates into Alzheimer neurofibrillary tangles. In particular, the transport of amyloid precursor protein is retarded when tau is elevated, suggesting a possible link between the two key proteins that show abnormal behavior in Alzheimer’s disease.
We have determined the biochemical and immunocytochemical localization of the heterogeneous microtubule-associated protein tau using a monoclonal antibody that binds to all of the tau polypeptides in both bovine and rat brain. Using immunoblot assays and competitive enzyme-linked immunosorbent assays, we have shown tau to be more abundant in bovine white matter extracts and microtubules than in extracts and microtubules from an enriched gray matter region of the brain. On a per mole basis, twice-cycled microtubules from white matter contained three times more tau than did twice-cycled microtubules from gray matter. Immunohistochemical studies that compared the localization of tau with that of MAP2 and tubulin demonstrated that tau was restricted to axons, extending the results of the biochemical studies. Tau localization was not observed in glia, which indicated that, at least in brain, tau is neuron specific. These observations indicate that tau may help define a subpopulation of microtubules that is restricted to axons. Furthermore, the monoclonal antibody described in this report should prove very useful to investigators studying axonal sprouting and growth because it is an exclusive axonal marker.
Tau is a family of closely related proteins (55,000-62,000 mol wt) which are contained in the nerve cells and copolymerize with tubulin to induce the formation of microtubules in vitro. All information so far has indicated that tau is closely apposed to the microtubule lattice, and there was no indication of domains projecting from the microtubule polymer lattice. We have studied the molecular structure of the tau factor and its mode of binding on microtubules using the quick-freeze, deep-etch method (QF.DE) and low angle rotary shadowing technique. Phosphocellulose column-purified tubulin from porcine brain was polymerized with tau and the centrifuged pellets were processed by QF.DE. We observed periodic armlike elements (18.7 +/- 4.8 nm long) projecting from the microtubule surface. Most of the projections appeared to cross-link adjacent microtubules. We measured the longitudinal periodicity of tau projections on the microtubules and found it to match the 6-dimer pattern better than the 12-dimer pattern. The stoichiometry of tau versus tubulin in preparations of tau saturated microtubules was 1:approximately 5.0 (molar ratio). Tau molecules adsorbed on mica took on rodlike forms (56.1 +/- 14.1 nm long). Although both tau and MAP1 are contained in axons, competitive binding studies demonstrated that the binding sites of tau and MAP1A on the microtubule surfaces are most distinct, although they may partially overlap.